0001213900-17-011753.txt : 20171113 0001213900-17-011753.hdr.sgml : 20171110 20171113083117 ACCESSION NUMBER: 0001213900-17-011753 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 39 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171113 DATE AS OF CHANGE: 20171113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: My Size, Inc. CENTRAL INDEX KEY: 0001211805 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37370 FILM NUMBER: 171193327 BUSINESS ADDRESS: STREET 1: 3 ARAVA ST. CITY: AIRPORT CITY STATE: L3 ZIP: 7010000 BUSINESS PHONE: 972-36009030 MAIL ADDRESS: STREET 1: 3 ARAVA ST. CITY: AIRPORT CITY STATE: L3 ZIP: 7010000 FORMER COMPANY: FORMER CONFORMED NAME: Mysize Inc. DATE OF NAME CHANGE: 20150317 FORMER COMPANY: FORMER CONFORMED NAME: TOPSPIN MEDICAL INC DATE OF NAME CHANGE: 20021226 10-Q 1 f10q0917_mysizeinc.htm QUARTERLY REPORT

U. S. Securities and Exchange Commission

Washington, D. C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File No. 001-37370

MY SIZE, INC.

(Exact name of registrant as specified in its charter)

Delaware

51-0394637

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
I.D. No.)

3 Arava St., pob 1026, Airport City, Israel, 7010000

(Address of principal executive offices)

+972-3-600-9030

Registrant’s telephone number, including area code:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.) Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
(Do not check if a smaller reporting company)		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 18,394,817 shares of common stock, par value $0.001 as of November 12, 2017.

MY SIZE, INC.

INDEX TO FORM 10-Q FILING

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017

TABLE OF CONTENTS

		PAGE
PART I - FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Interim Financial Statements (Unaudited)	1
	Condensed Consolidated Interim Balance Sheets	3
	Condensed Consolidated Interim Statements of Comprehensive Loss	4
	Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity (Deficit)	5
	Condensed Consolidated Interim Statements of Cash Flows	8
	Notes to Condensed Consolidated Interim Financial Statements	9
Item 2.	Management’s Discussion & Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosure About Market Risk	18
Item 4.	Controls and Procedures	18

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	19
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	21
Item 5	Other information	21
Item 6.	Exhibits	21

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements.

My Size, Inc. and Subsidiaries

Condensed Consolidated Interim

Financial Statements

As of September 30, 2017

(unaudited)

U.S. Dollars in Thousands

My Size, Inc.

Condensed Consolidated Interim Financial Statements as of September 30, 2017 (Unaudited)

Contents

	Page

Condensed Consolidated Interim Balance Sheets	3

Condensed Consolidated Interim Statements of Comprehensive Loss	4

Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity (Deficit)	5-7

Condensed Consolidated Interim Statements of Cash Flows	8

Notes to Condensed Consolidated Interim Financial Statements	9-14

My Size, Inc.

Condensed Consolidated Interim Balance Sheets

U.S. dollars in thousands (except share data and per share data)

	September 30,			December 31,
	2017			2016
	(Unaudited)			(Audited)
	$ thousands			$ thousands
Assets
Current Assets:
Cash and cash equivalents		14			34
Other receivables and prepaid expenses		304			1,401
Restricted cash		69			62
Total current assets		387			1,497

Investment in marketable securities		246			579
Property and equipment, net		67			74
		313			653

Total assets		700			2,150

Liabilities and stockholders’ equity
Current liabilities
Trade payable		315			229
Accounts payable		442			316
Warrants, Derivative and share based liabilities		435			80

Total current liabilities		1,192			625

COMMITMENTS AND CONTINGENCIES
Stockholders’ equity (Deficit):
Capital stock -
Common stock of $ 0.001 par value - Authorized: 50,000,000 shares; Issued and outstanding: 18,078,218 and 17,405,359 As of September 30, 2017 and December 31, 2016, respectively		18			17
Additional paid-in capital		14,740			13,347
Available for sale reserve		-			(93	)
Accumulated other comprehensive loss		(87	)		(102	)
Accumulated deficit		(15,163	)		(11,644	)

Total stockholders’ equity (Deficit)		(492	)		1,525
Total liabilities and stockholders’ equity		700			2,150

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

My Size, Inc.

Condensed Consolidated Interim Statements of Comprehensive Loss

U.S. dollars in thousands (except share data and per share data)

	Nine-Months Ended September 30,						Three-Months Ended September 30,						Year ended December 31,
	2017			2016			2017			2016			2016
	$ thousands (Unaudited)			$ thousands (Unaudited)			$ thousands (Unaudited)			$ thousands (Unaudited)			$ thousands (Audited)
Operating expenses
Research and development		624			500			213			172			727
Marketing, General and administrative		2,667			1,359			611			434			1,859

Total operating expenses		3,291			1,859			824			606			2,586
Operating loss		(3,291	)		(1,859	)		(824	)		(606	)		(2,586	)
Financial (expenses) income, net		(228	)		(2,261	)		17			(118	)		(1,748	)

Net loss from continuing operations		(3,519	)		(4,120	)		(807	)		(724	)		(4,334	)
Other comprehensive loss:

Gain (loss) on available for sale securities		93			67			67			(527	)		(24	)
Foreign currency translation differences		15			(49	)		16			35			2

Total comprehensive loss		(3,411	)		(4,102	)		(724	)		(1,216	)		(4,356	)

Basic and diluted loss per share		(0.19	)		(0.26	)		(0.04	)		(0.04	)		(0.27	)
Basic and diluted weighted average number of shares outstanding		17,599,340			15,741,967			17,625,440			16,584,354			16,345,499

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

My Size, Inc.

Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited)

U.S. dollars in thousands (except share data and per share data)

					Additional		Available			Foreign						Total Stockholders’
	Common stock				paid-in		for sale			currency			Accumulated			Equity
	Number		Amount		capital		reserve			transaction			Deficit			(Deficit)

Balance as of January 1, 2017		17,405,359		17		13,347		(93	)		(102	)		(11,644	)		1,525

Total comprehensive loss		-		-		-		93			15			(3,519	)		(3,411	)
Stock-based compensation related to options granted to consultants		-		-		126		-			-			-			126
Warrants converted and exercised into equity		80,359		*()**		60		-			-						60
Issuance and receipts on account of shares		592,500		1		1,207		-			-			-			1,208
Balance as of September 30, 2017		18,078,218		18		14,740		-			(87	)		(15,163	)		(492	)

	Common stock				Additional paid-in			Available for sale			Foreign currency			Accumulated			Total stockholders’
	Number		Amount		capital			reserve			transaction			Deficit			Equity

Balance as of January 1, 2016		15,313,793		15		4,853			(67	)		(104	)		(7,310	)		(2,613	)

Total comprehensive loss		-		-		-			67			(49	)		(4,120	)		(4,102	)
Stock-based compensation related to options granted to consultants		-		-		(33	)		-			-			-			(33	)
Convertible loans converted to equity		2,091,566		2		6,728			-			-			-			6,730
Warrants reclassified to equity as a result of amended exercise price currency		-		-		1,041			-			-			-			1,041

Balance as of September 30, 2016		17,405,359		17		12,589			-			(153	)		(11,430	)		1,023

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

My Size, Inc.

Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited)

U.S. dollars in thousands (except share data and per share data)

					Additional		Available			Foreign						Total Stockholders’
	Common stock				paid-in		for sale			currency			Accumulated			Equity
	Number		Amount		capital		reserve			transaction			Deficit			(Deficit)

Balance as of July 1, 2017		17,605,359		17		14,052		(67	)		(103	)		(14,356	)		(457	)

Total comprehensive loss		-		-		-		67			16			(807	)		(724	)
Stock-based compensation related to options granted to consultants		-		-		53		-			-			-			53
Warrants converted and exercised into equity		80,359		*()**		60											60
Issuance and receipts on account of shares		392,500		1		575		-			-			-			576
Balance as of September 30, 2017		18,078,218		18		14,740		-			(87	)		(15,163	)		(492	)

(*) Less than $1.

	Common stock				Additional paid-in			Available for sale			Foreign currency			Accumulated			Total stockholders’
	Number		Amount		capital			reserve			transaction			Deficit			equity

Balance as of July 1, 2016		15,313,793		15		11,155			527			(187	)		(10,706	)		804

Total comprehensive loss		-		-		-			(527	)		34			(724	)		(1,217	)
Stock-based compensation related to options granted to consultants		-		-		(39	)		-			-			-			(39	)
Convertible loans converted to equity		2,091,566		2		1,473			-			-			-			1,475

Balance as of September 30, 2016		17,405,359		17		12,589			-			(153	)		(11,430	)		1,023

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

My Size, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Audited)

U.S. dollars in thousands (except share data and per share data)

	Common stock				Additional paid-in			Available for sale			Foreign currency			Accumulated			Total stockholders’ equity
	Number		Amount		capital			reserve			transaction			Deficit			(Deficit)

Balance as of December 31, 2015		15,313,793		15		4,855			(69	)		(104	)		(7,310	)		(2,613	)

Total comprehensive loss		-		-		-			(24	)		2			(4,334	)		(4,356	)
Stock-based compensation related to options granted to consultants		-		-		(23	)		-			-			-			(23	)
Convertible loans converted to equity		2,091,566		2		7,528			-			-			-			7,530
Warrants reclassified to equity as a result of amended exercise price currency		-		-		987			-			-			-			987

Balance as of December 31, 2016		17,405,359		17		13,347			(93	)		(102	)		(11,644	)		1,525

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

My Size, Inc.

Condensed Consolidated Interim Statements of Cash Flows

	Nine-Months Ended September 30,						Three-Months Ended September 30,						Year ended December 31,
	2017			2016			2017			2016			2016
	$ thousands (Unaudited)			$ thousands (Unaudited)			$ thousands (Unaudited)			$ thousands (Unaudited)			$ thousands (Audited)
Cash flows from operating activities:
Net loss		(3,519	)		(4,120	)		(807	)		(724	)		(4,334	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		22			17			7			6			24
Amortization of warrant, convertible loans and derivative		(251	)		2,260			(101	)		117			(182	)
Revaluation of PUT options		-			-			-			-			776
Revaluation of investment in marketable securities		472			-			132			-			1,233
Stock based compensation- equity		126			(33	)		53			(39	)		(23	)
Stock based compensation- liability		265			-			88			-			-
Decrease (increase) in receivables and prepaid expenses		115			(43	)		61			(39	)		(27	)
Increase in derivative liabilities		126			-			(27	)		-			80
Increase (decrease) in trade payable		64			44			127			(62	)		86
Increase (decrease) in other accounts payable		108			127			(60	)		57			208

Net cash used in operating activities		(2,472	)		(1,748	)		(527	)		(684	)		(2,159	)

Cash flows from investing activities:

Purchase of property and equipment		(8	)		(31	)		(1	)		(8	)		(36	)

Net cash used in investing activities		(8	)		(31	)		(1	)		(8	)		(36	)

Cash flows from financing activities:
Repayment of a loan		(10	)		(25	)		-			-			(25	)
Proceeds from issuance of shares, warrants and convertible loans		2,506			1,043			491			739			1,339

Net cash provided by financing activities		2,496			1,018			491			739			1,314

Effect of exchange rate changes on cash and cash equivalents		(36	)		(15	)		(77	)		(2	)		(4	)

Increase (Decrease) in cash and cash equivalents		(20	)		(776	)		(114	)		45			(885	)
Cash and cash equivalents at the beginning of the period		34			919			128			98			919

Cash and cash equivalents at the end of the period		14			143			14			143			34

Non cash transactions
Warrants reclassified to equity as a result of amended exercise price currency		-			987			-			-			987
Conversion of loan to equity		-			4,939			-			-			4,846

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

My Size, Inc.

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 1 - General

My Size Inc. (the “Company”), is a dual listed publicly traded company whose common stock is publicly trading on the TASE since September 2005 (under the name Topspin Medical Inc) and on the NASDAQ Capital Market (“NASDAQ”) since July 25, 2016. The Company has developed a measurement technology based on algorithms with broad applications in a variety of areas, from the apparel e-commerce market to Do It Yourself (“DIY”) smartphone and tablet apps. The technology is driven by several patent-pending algorithms which are able to calculate and record measurements in a variety of novel ways.

Since February 2014, the Company also operates via a wholly-owned subsidiary, My Size (Israel) 2014 Ltd., a company registered in Israel.

Since inception, the Company has incurred losses and negative cash flows from operations, and as of the date of the report has an accumulated loss amounting to approximately $15.1 million. The Company has financed its operations mainly through fundraising from private investors.

As of September 30, 2017, the Company entered into agreements pursuant to which it raised an aggregate of $8,795 of which $5,753 and $1,410 were received in cash and marketable securities, respectively. The marketable securities are shares of common stock of Diamante Minerals Inc (“DIMN”), which are accounted as a financial asset available for sale and presented in the Company’s balance sheet under investment in marketable securities.

As of September 30, 2017, the Company has $1,177 and $455 in guaranteed notes and checks, respectively as remaining balance from the amounts described above. The guarantee has been provided by an ungraded financial institution. Subsequent to September 30, 2017, $236 of the guarantee notes have been redeemed in cash.

Based on the projected cash flows and cash balances as of September 30, 2017, the Company’s Management is of the opinion that without further fund raising it will not have sufficient resources to enable it to continue its operating activities including the development, and marketing of its products for a period of at least 12 months from the date of approval of these financial statements. As a result, there is substantial doubt about the Company’s ability to continue as a going concern.

Management’s plans include the continued commercialization of the Company’s products and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships, see also note 7. There can be no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to cease operations.

The financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern.

Note 2 - Significant Accounting Policies

Unaudited condensed consolidated interim financial statements:

The accompanying unaudited condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The unaudited condensed consolidated financial statements are comprised of the financial statements of the Company and its subsidiaries collectively referred to as the Company. In management’s opinion, the interim financial data presented includes all adjustments necessary for a fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles (“GAAP”) has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2017.

These unaudited condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2016.

Use of estimates:

The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates.

My Size, Inc.

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 3 - Financial Instruments

Fair value of financial instruments:

ASC 820, “Fair Value Measurements and Disclosures”, defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

	Level 1 -	Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.
	Level 2 -	Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
	Level 3 -	Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends.

The carrying amounts of cash and cash equivalents, other accounts receivable, accounts payable and other accounts payable approximate their fair value due to the short-term maturities of such instruments.

The Company holds shares in a publicly-traded company - Diamante Minerals, Inc. which are classified as available-for-sale equity securities. The marketable securities have readily determinable fair market values that are calculated based on the share price on the measurement date and ranked as Level 1 assets.

September 30, 2017

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities

246

My Size, Inc.

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 3 - Financial Instruments (cont’d)

	September 30, 2017
	Fair value hierarchy
	Level 1		Level 2		Level 3
Financial liabilities
Derivative liabilities		-		299		-
Warrants and share based liabilities		-		136		-

December 31, 2016

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities

579

December 31, 2016

Fair value hierarchy

Level 1

Level 2

Level 3

Financial liabilities

Derivative liabilities

At September 30, 2017, the fair value (based on quoted market prices) of these securities was $246. During the nine month period ended September 30, 2017 the recognized loss was $472 (At December 31, 2016, gross unrecognized loss, recognized loss and fair value (based on quoted market prices) of these securities were $24, $1,233 and $579, respectively).

My Size, Inc.

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 4 - Stock Based Compensation

The stock based expense (income) recognized in the financial statements for services received from non-employees is related to Marketing, General and Administrative expenses and shown in the following table:

	Nine months ended September 30,					Three months ended September 30,					Year ended December 31,
	2017		2016			2017		2016			2016

Stock-based compensation expense - equity awards		126		(33	)		53		(39	)		(23	)
Stock-based compensation expense - liability awards		265		-			88		-			-

		391		(33	)		141		(39	)		(23	)

In December 2016, the Company entered into a consulting agreement with a consultant ( “Consultant1”) pursuant to which Consultant1 is providing services in connection with marketing strategies, micro and macro-economic issues and for the promotion of the Company’s marketing, business, products and operations through smartphone applications. The agreement is for a period of 18 months commencing October 2016.

In consideration for services provided under the consulting agreement, the Company agreed to issue Consultant1 25,000 shares of common stock of the Company which are to be issued over six quarters as follows: 4,150 issued over each of the first five quarters and a sixth installment of 4,250 to be issued on the sixth quarter of the consulting agreement. In addition, the Company has agreed to issue to Consultant1 stock options to purchase up to 40,000 shares of the Company’s common stock, exercisable not later than March 31, 2018 at an exercise price of NIS18 per share.

In addition, the Company undertook to pay the balance of the consideration for the sale of the shares by Consultant1 up to the sum of NIS500,000. If the consideration for the sale of the shares falls below 90% of the shares’ price on the stock exchange on the date of sale, the Company shall pay Consultant1 the difference. The Company may decide at its own discretion whether to make such payment in cash or shares of common stock.

On March 21, 2017, the shareholders of the Company approved the adoption of the 2017 Consultant Equity Incentive Plan at the Company’s Annual Meeting of Stockholders. The approval was required for the issuance of the options and shares of common stock of the Company issued to Consultant1.

During the nine-month period ended September 30, 2017, costs in the sum of $(4) ($90 during 2016) were recorded by the Company and an undertaking to pay the balance of the consideration was recognized in the sum of $124 ($80 during 2016) according to the fair value of the undertaking.

In December 2016, the Company engaged a consultant (“Consultant2”) to provide services to the Company with respect to marketing strategy and public relations, including potential investors relations. For such consulting services, the Company agreed to issue to Consultant2 options to purchase up to 2,000,000 shares of the Company’s common stock at variable exercise prices ranging from $3.50 to $9.00 per share. The options are exercisable for periods ranging from 12 months (or 6 months from filing date of registration statement) to 36 months. The issuance of the options under the agreement was subject to the receipt of all the approvals required by the laws applicable to the Company, including stock exchange approvals and the approval by the Company’s shareholders to adopt an equity incentive plan for consultants. The equity incentive plan for consultants was approved by the shareholders on March 21, 2017 at the Company’s Annual Meeting of Stockholders.

On May 16, 2017, the Company and the Consultant2 entered into an amendment to the consulting agreement pursuant to which the strike prices of the options were amended to a range from $1.50 to $5.00 per share.

Following initial grant, the Company reclassified the options from equity accounted under ASC 505-50 to derivative liability accounted under ASC 815.

The expense recognize in the second and third quarters, including the cost associates with the consulting service attributed to the reporting period and the revaluation of the derivative amounted to $186.

An amount of $88 and $27 was recorded in the balance sheet as warrants and share based liabilities and share based payments respectively.

In April 2017, the Company engaged a consultant (“Consultant3”) to provide services to the Company with respect to financing and strategic advisory for a period of two years. For such consulting services, the Company agreed to pay a monthly retainer and to issue to the Consultant3 50,000 shares of the Company common stock and 31,250 shares each quarter thereafter.

During the nine-month period ended September 30, 2017, costs in the sum of $76 were recorded by the Company as stock-based compensation expense- equity awards.

My Size, Inc.

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 5 - Contingencies and Commitments

Further to Note 10a to the Annual Report on Form 10-K for the year ended December 31, 2016:

On December 27, 2015, the Company received a legal complaint (the “Complaint”). The defendants named in the Complaint were the Company, all the members of the Board of Directors of the Company, the officers of the Company, Mrs. Shoshana Zigdon, a shareholder and related party of the Company, as well as two additional defendants who are not shareholders of the Company. The plaintiff alleged that the Company violated its obligation to register shares purchased by the plaintiff on July 3, 2014 (the “Original Shares”) for trade with the Tel Aviv Stock Exchange.

The Company and plaintiff entered into a settlement agreement (the “Settlement”) dated June 20, 2017 following a mediation process. Pursuant to the Settlement, the Company agreed to make a payment to the plaintiff of NIS325,000 (the “Down Payment”) within 30 days of the date of the Settlement. Additionally, the Company is obligated to register the Original Shares within a specified time frame. Moreover, pursuant to the Settlement, the Company agreed to issue, within 60 days, 80,358 additional shares of common stock to the plaintiff (the “New Shares”), which New Shares shall be registered, to be deposited in escrow and sold for the benefit of plaintiff. To the extent the Company will not issue the unrestricted New Shares within 60 days of the Settlement, the plaintiff has a right, at his sole discretion, to resume the legal proceedings pursuant to the Complaint, provided he deposits the Down Payment in an escrow account, pending the Court’s final adjudication of the Complaint. Additionally, the Settlement provides that to the extent the aggregate proceeds from the sale of the Original Shares and the New Shares is less than NIS1,600,000, the Company will either complement the difference in cash or shall issue to the plaintiff additional shares of common stock in lieu thereof, at the Company’s sole discretion.

During the three month period ended September 30 2017, the Company issued shares and recorded an amount of $60 in equity and paid the plaintiff the Down Payment. As of September 30, 2017, The Company recorded a derivative liability in the amount of $176.

Further to Note 10b to the Annual Report on Form 10-K for the year ended December 31, 2016., The Company has paid its obligation to the investor in full, As of the date on which the financial statements were signed.

Further to Note 10c to the annual report on Form 10-K for the year ended December 31, 2016: On September 5, 2017, the Court rendered a judgment in the case (the “Judgment”), under which the complaint against the Company was accepted, the complaint against the CEO Mr. Ronen Luzon was rejected and the Company’s counter-claim was rejected.

The Judgment included: (1) A declaratory remedy, under which the Company breached its contractual undertakings toward the plaintiffs, to list their shares both on the Tel Aviv Stock Exchange and on NASDAQ; (2) An Order that the Company take any and all actions required for the listing of the plaintiffs shares, including instructing the Company’s transfer agent to remove the legend or any other restriction from the plaintiffs stock certificate and to issue them with new stock certificates free and clear from any restriction; (3) An order that the registration company of Bank Hapoalim electronically list all of the plaintiffs’ shares detailed in the complaint on the electronic trading system; (iv) A rejection of the complaint against the Company’s CEO Mr. Luzon (4) An order that the Company pay the plaintiffs costs in the amount of NIS 70,000 (which amount is linked to the Israeli CPI and bearing legal interest from the Judgment date until actual payment if effected). Other than the payment of costs the Judgment bears no financial liability on the Company. On October 3 2017 the Company appealed the Judgment with the Supreme Court of Israel and simultaneously, filed with the Supreme Court a Motion for Stay of Execution of the Judgment, pending the outcome of the appeal. On October 19, 2017, the respondents filed their response to the Motion and on November 2, 2017 the Company filed its reply the respondents’ response. On November 8, 2017, the Supreme Court upheld the Motion to Stay and ordered that the execution of the Judgment will be stayed pending the outcome of the Appeal, provided that the Company will deposit in the Court’s treasury an autonomous Israeli CPI linked bank guarantee in an amount of NIS 1,700,000, to cover the respondents’ potential damages should the appeal be ultimately denied.

The Company received legal advice from its counsel that the burden of proof that the Judgment is wrong and should be reversed lies with the appellant. Consequently, the Company believes that it is more likely than not that the appeal will be denied rather than being accepted. In the event that the Appeal is denied, no direct financial liability will be imposed on the Company (other than legal costs which the court may order the losing side to pay).

My Size, Inc.

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 5 - Contingencies and Commitments (cont’d)

On May 3, 2017, Lightcom (Israel) Ltd., an Israeli company, alleging that it is a shareholder of the Company, filed a motion (the “Motion”) with the Tel Aviv District Court (Financial Division) to approve an action against the Company as a shareholders’ class action. The subject matter of the action appears to be a report filed by the Company on April 19, 2017. The Court ordered the Company to respond to the motion by November 15, 2017. The Motion alleges, inter alia, that the Company’s report date April 19, 2017 regarding its engagement with the Israeli Post was false and misleading, and that as a result thereof financial damages have been incurred by two purported classes of shareholders: (i) any shareholder who sold Company’s shares as of April 20, 2017 and until April 27, 2017, with respect to damage directly caused by such sale and (ii) any shareholder who held shares on April 20, 2017 and subsequent to April 27, 2017 with respect to damage caused by permanent adverse effect to the shares’ value. The alleged financial damage caused to members of both classes is estimated at NIS 18.8 million. The Company reviewed the Motion initially with its legal counsel and retained an expert to review and analyze the allegations and data upon which the Motion is based. The Company’s management, after considering the conclusions of a report issued by a third party expert and an opinion of U.S. legal counsel, is of the opinion that the chances that the Class Motion will be denied exceed the risk that it will be approved. In the event that the Class Motion will be approved, the complaint will become a class action which will be heard by the Court on its merits. Should this occur, the Company will respond to the Class Motion in the time frame ordered by the Court.

Note 6 - Significant Events During the Reporting Period

	a.	In February 2017, the Board of Directors approved agreements with investors that will provide an investment for a total amount of $200 in exchange for 200,000 shares of common stock of the Company. In addition, the Company will issue warrants exercisable for an aggregate of 250,000 shares of common stock of the Company until December 22, 2017 at an exercise price of $3.50 per share.

	b.	On June 5, 2017, the Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC notifying the Company that for the preceding 30 consecutive business days, the Company’s common stock did not maintain a minimum Market Value of Listed Securities of $35 million (“MVLS Requirement”) per share as required by NASDAQ Listing Rule 5550(b)(2).

In accordance with NASDAQ Listing Rule 5810(c)(3)(C), the Company has a grace period of 180 calendar days, or until December 4, 2017, to regain compliance with NASDAQ Listing Rule 5550(b)(2). The Company will endeavor to rectify the situation and to meet the MVLS Requirement.

On August 16 2017, the Board of Directors approved agreements with three private investors who will provide investment totaling $780 in exchange for 780,000 shares of common stock of the Company.

During August and September 2017, the Company received $341 from the investments in cash. The remaining amount of the investment is guaranteed by notes. Subsequent to September 30 2017, $236 was received in cash.

My Size, Inc.

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 6 - Significant Events During the Reporting Period (cont’d)

	d.	On September 26, 2017, the Company was notified (the “Notification Letter”) by The NASDAQ Stock Market, LLC (“NASDAQ”) that it is not in compliance with the minimum bid price requirements set forth in NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and NASDAQ Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on The NASDAQ Capital Market and, at this time, the common stock will continue to trade on The NASDAQ Capital Market under the symbol “MYSZ”.

		The Notification Letter provides that the Company has 180 calendar days, or until March 26, 2018, to regain compliance with NASDAQ Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by March 26, 2018, an additional 180 days may be granted to regain compliance, so long as the Company meets The NASDAQ Capital Market continued listing requirements (except for the bid price requirement) and notifies NASDAQ in writing of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then NASDAQ will notify the Company of its determination to delist the Company's common stock, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel.

		The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the minimum bid price requirement under the NASDAQ Listing Rules.

Note 7 - Subsequent Events

On October 26, 2017, My Size, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) to sell original issue discount non-convertible notes (the “Notes”) and warrants (the “Warrants”) to certain accredited investors in a private placement transaction (the “Offering”). In connection with the Offering, the Company issued (i) Notes with a principal amount of $1.33 million and (ii) 888,888 Warrants. The Offering resulted in gross proceeds to the Company of approximately $1.2 million, before deducting placement agent and other offering expenses.

The Notes will be due on the earlier of the four month anniversary from the date of their issuance or the completion of another equity offering. The Warrants have a five-year term and are exercisable at a price of $0.75 per share.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion along with our financial statements and the related notes included in this report. The following discussion contains forward-looking statements that are subject to risks, uncertainties and assumptions, including those discussed under “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2016. Our actual results, performance and achievements may differ materially from those expressed in, or implied by, these forward-looking statements.

Results of Operations

Nine and three months ended September 30, 2017 compared to nine and three months ended September 30, 2016

From inception through September 30, 2017, we have sustained an accumulated deficit of approximately $15.1 million. From inception through September 30, 2017, we have not generated any revenue from operations and expect to incur additional losses to perform further research and development activities and do not currently have any commercial products. Our product development efforts are still in their early stages and we are currently unable to estimate the cost or time they will take to complete.

Research and Development Expenses

Our research and development expenses for the nine months ended September 30, 2017 amounted to $624,000 compared to $500,000 for the nine months ended September 30, 2016. The increase between the corresponding periods primarily resulted from increased expenses related to subcontractors and the increased expenses associated with the hiring of new employees.

Our research and development expenses for the three months ended September 30, 2017 amounted to $213,000 compared to $172,000 for the three months ended September 30, 2016. The increase between the corresponding periods primarily resulted from increased expenses related to subcontractors and the increased expenses associated with the hiring of new employees.

Marketing, General and Administrative Expenses

Our marketing, general and administrative expenses for the nine months ended September 30, 2017 amounted to $2,667,000 compared to $1,359,000 for the nine months ended September 30, 2016. The increase between the corresponding period in expenses was derived mainly from share based payments, increases in public relations and investor relations expenses and from increased expenses associated with the hiring of new employees.

Our marketing, general and administrative expenses for the three months ended September 30, 2017 amounted to $611,000 compared to $434,000 for the three months ended September 30, 2016. The increase between the corresponding period in expenses was derived mainly from share based payments, increases in public relations and investor relations expenses and from increased expenses associated with the hiring of new employees.

Financial income and expense, net

Our financial expenses for the nine months ended September 30, 2017 amounted to $228,000, compared to financial expense of $2,261,000 for the nine months ended September 30, 2016. The decrease between the corresponding periods in financial expenses was derived mainly from the creation and revaluation of the components of the options, derivatives and investment in marketable securities.

Our financial income for the three months ended September 30, 2017 amounted to $17,000 compared to financial expense of $118,000 for the three months ended September 30, 2016. The decrease between the corresponding periods in financial expenses was derived mainly from the creation and revaluation of the components of the options, derivatives and investment in marketable securities.

Net Loss from continuing operations

As a result of the foregoing research and development, marketing general and administrative expenses, and financial expenses, our net loss from continuing operations for the nine months ended September 30, 2017 was $3,519,000, compared to a net loss from continuing operations for the nine months ended September 30, 2016 of $4,120,000. The main reasons for the change between the corresponding periods is due to a decrease in finance expenses mainly from the creation and revaluation of the components of the options, derivatives and investment in marketable securities in the corresponding period. This decrease was partially offset by an increase in share based payments, increases in public relations and investor relations expenses and from increased expenses associated with the hiring of new employees.

Our net loss from continuing operations for the three months ended September 30, 2017 was $807,000, compared to a net loss from continuing operations for the three months ended September 30, 2016 of $724,000. The decrease between the corresponding periods was mainly due to finance expenses from the revaluation of options and derivatives in the corresponding period. This decrease was partially offset by an increase in share based payments, increases in public relations and investor relations expenses and from increased expenses associated with the hiring of new employees.

Liquidity and Capital Resources

Since inception, we have funded our operations primarily through private offerings of our equity securities.

As of September 30, 2017, we had cash and cash equivalents of $14,000 as compared to $34,000 as of December 31, 2016.

Net cash used in operating activities was $2,472,000 for the nine months ended September 30, 2017 compared to $1,748,000 for the nine months ended September 30, 2016.

The increase in cash used in operating activities mainly resulted from increased payments to service providers and Company employees. The Company has also incurred expenses not in the ordinary course of its business mainly from the registration of patents, the listing of the common stock on the NASDAQ Capital Market and legal expenses associated with lawsuits involving the Company.

Net cashed used in investing activities was $8,000 for the nine months ended September 30, 2017 compared to $31,000 for the nine months ended September 30, 2016. The negative cash flow resulted from purchase of equipment.

Net cash provided by financing activities was $2,496,000 for the nine months ended September 30, 2017 compared to $1,018,000 for the nine months ended September 30, 2016. The cash flows from financing activities for the nine months ended September 30, 2017 was mainly due to realization of guarantees.

On August 16, 2017, the Board of Directors approved agreements with three private investors who will provide an investment totaling $780 in exchange for $780,000 shares of common stock of the Company.

During August and September 2017, the Company received $341 from the investments in cash. The remaining amount of the investment is guaranteed by notes issued by an ungraded financial institution in favor of the Company. In the event that the investor does not fulfill its obligation to purchase the shares of the Company’s Common Stock with respect to which the guarantee note has been issued, then the Company may call the guarantee note; provided, however, the existing guarantee note currently expires on November 14, 2017. As of the date of this report, the Company is in discussions with the investor regarding the extension of the guarantee note, however, an extended guarantee note has not yet been approved or put in place. Subsequent to September 30 2017, $236 was received in cash.

On October 26, 2017, the Company entered into a securities purchase agreement to sell original issue discount non-convertible notes (the “Notes”) and warrants (the “Warrants”) to certain accredited investors in a private placement transaction (the “Offering”). In connection with such Offering, the Company issued (i) Notes with a principal amount of $1.33 million and (ii) 888,888 Warrants. The Offering resulted in gross proceeds to the Company of approximately $1.2 million, before deducting placement agent and other offering expenses.

The Notes are due on the earlier of the four month anniversary from the date of their issuance or the completion of another equity offering. The Warrants have a five-year term and will have an exercise price of $0.75 per share.

As of September 30, 2017, the Company has $1,177 and $455 in guaranteed notes and checks, respectively as remaining balance from the amounts described above. The guarantee has been provided by an ungraded financial institution. As previously disclosed, the checks have not been honored, continue to remain outstanding, and no shares will be issued on these funds until the entire outstanding amount of the checks has been fully paid.

Subsequent to September 30, 2017, the sum of $236 of the guarantee notes has been redeemed in cash.

Based on the projected cash flows and its cash balances as of September 30, 2017, the Company’s Management is of the opinion that without further fund raising it will not have sufficient resources to enable it to continue its operating activities including the development, and marketing of its products for a period of at least 12 months from the date of approval of these financial statements. As a result, there are substantial doubt about the Company’s ability to continue as a going concern.

Management’s plans include the continued commercialization of their products and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to cease operations.

The financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern.

A downturn in the United States stock and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our shares of common stock or the debt securities may cause us to be subject to restrictive covenants. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek additional financing. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.

Off-Balance Sheet Arrangements

We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

Application of Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this report, we believe that the accounting policies discussed below are critical to our financial results and to the understanding of our past and future performance, as these policies relate to the more significant areas involving management’s estimates and assumptions. We consider an accounting estimate to be critical if: (1) it requires us to make assumptions because information was not available at the time or it included matters that were highly uncertain at the time we were making our estimate; and (2) changes in the estimate could have a material impact on our financial condition or results of operations.

Equity-based compensation

The Company applies ASC 505-50, “Equity-Based Payments to Non-Employees” with respect to options and warrants issued to non-employees.

Item 3. Quantitative and Qualitative Disclosure About Market Risk.

Not required for a smaller reporting company.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We carried out an evaluation required by the Securities Exchange Act of 1934, as amended (the “Exchange Act”), under the supervision and with the participation of the Company’s management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act, as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

Changes in Internal Controls

During the most recent fiscal quarter, there has not occurred any change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II – Other Information

Item 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

We are not currently a party to any material legal proceedings except as described below.

●

On December 27, 2015, the Company received a legal complaint. The defendants named in the complaint are the Company, the members of the Board of Directors of the Company, Mrs. Shoshana Zigdon, a shareholder and related party in the Company, as well as two additional defendants who are not shareholders of the Company. The plaintiff alleges that the Company violated its obligation to register his shares for trade with the Tel Aviv Stock Exchange causing a total of NIS 2,622,500 damage. The plaintiff seeks relief against the defendants through financial compensation at the rate of the aforementioned alleged damage; additional compensation of NIS 400,000 due to mental anguish; and if and to the extent that until the time the plaintiff can sell its shares on the Stock Exchange (“the Exercise Date”), the rate of a Company share will rise above the amount of NIS 20.98 (“the Base Rate”), an additional amount at the rate of the difference between the Base Rate and the highest rate of a Company share between the time the claim was submitted and the exercise date; and also court costs and attorney’s fees of the plaintiff.

In a pre-trial hearing dated March 7, 2016, the court decided that disclosure would take place and disclosure affidavits along with copies of the documents specified therein were exchanged between the parties. Following the recommendation of the court, on March 20, 2016, the plaintiff filed a notice of deletion of certain defendants including board and management members, excluding the chairman of the Board and the CEO of the Company from the statement of claim.

All pre-trial preliminary proceedings as well as submission of all evidentiary affidavits and expert opinions by both parties have been completed. Pursuant to the Israeli Court’s recommendation, the case was referred to mediation by the honorable Judge (Rtd.) Hilla Gerstel, former president of the Central District Court.

The mediation has been completed and the Company and the plaintiff entered into a settlement agreement (the “Settlement”) dated June 20, 2017. Pursuant to the Settlement, the Company agreed to make a payment to the plaintiff of NIS325,000 (as of the date hereof, approximately USD$92,000) (the “Down Payment”) within 30 days of the date of the Settlement. Additionally, the Company is obligated to register the Original Shares within a specified time frame. Additionally, pursuant to the Settlement, the Company agreed to issue, within 60 days, 80,358 additional shares of common stock to the plaintiff (the “New Shares”), which New Shares shall be registered, to be deposited in escrow and sold for the benefit of plaintiff. Such New Shares shall be sold at a maximum aggregate price of NIS10,000 or an amount constituting not more than 2% of the average volume of trades within the last 90 days, whichever higher, in one single trading day. To the extent the Company does not issue the unrestricted New Shares within 60 days, the Plaintiff has a right, at his exclusive discretion, to resume the proceedings pursuant to the complaint, provided he will deposits the Down Payment in an escrow account, pending the Court’s final adjudication of the complaint. Additionally, the Settlement provides that to the to the extent the aggregate proceeds from the sale of the Original Shares and the New Shares is less than NIS1,600,000, the Company will either complement the difference in cash or shall issue to the plaintiff additional shares of common stock in lieu thereof, at the Company’s sole discretion.

●

On May 17, 2012, the Company executed a loan agreement for a loan which is convertible into shares of the Company’s common stock with an investor. Pursuant to the loan agreement, the Company received a total of NIS200,000 upon execution of the loan agreement and was to receive an additional amount of NIS100,000 at the end of a period not to exceed 21 days, during which the investor would conduct due diligence with respect to the Company. In addition, the loan agreement provided for additional investments up to a total of NIS2,000,000. Pursuant to the loan agreement, the investor could convert the loan into common shares of the Company at a price per share equal to NIS0.97. If the loans were not converted into shares of the Company’s common stock, the loans were to be repaid one year after the date of the loan agreement plus annual interest of 10%. On February 18, 2015, the Company received a claim in a summary judgement for the investor’s demand of payment of the loan amount of NIS200,000, which was paid to the Company on May 17, 2012, plus interest of 10% annually from May 20, 2012 until payment of the debt, which as of the date of filing of the claim was NIS258,000. On June 13, 2016, a settlement agreement was entered into between the parties pursuant to which, in consideration for the final and conclusive annulment of all claims and/or demands raised by the plaintiff against the Company, the Company agreed to pay the plaintiff the sum of NIS250,000 by wire transfer of about NIS95,000 and by the forfeiture of the sum of approximately NIS155,000 which had been deposited with the court. An additional amount of NIS50,000 was to be paid within twelve months from the approval of the settlement agreement by the court or on the closing date of a public offering of Company shares on a stock exchange in the United States. As of the date on which the financial statements were signed, the Company has paid its obligation to the investor in full.

●

On September 9, 2015, fourteen shareholders filed a complaint against the Company and its CEO Mr. Ronen Luzon, alleging that in accordance with agreements signed between plaintiffs and the Company, the plaintiffs are entitled to register their shares for sale with the stock market, while the Company allegedly breached its obligation and refrained from doing its duty to register the plaintiffs’ shares. The plaintiffs sought declaratory remedy that they are entitled to register their shares and also request the right to split their remedies so they will also be able subsequently to claim from the defendants compensation for any financial damage caused by the Company’s failure to register their shares, including damage due to any decrease in the shares’ price during the period the shares should have been registered. On November 5, 2015, the Company filed its defense and a counter claim against the plaintiffs and against two additional defendants (who are not plaintiffs) Mr. Asher Shmuelevitch and Mr. Eitan Nahum. In its counter claim, the Company alleged that the agreements by force of which the counter defendants hold their shares are defunct, based on fraud, as the counter defendants never paid and never intended to pay the agreed consideration for their shares. The Company further alleged that Mr. Shmuelevitch used his position as a director and controlling shareholder of the Company to knowingly cause the Company to enter such defunct agreements. The Company moved the court to dismiss the complaint against it, declare that all agreements with the counter defendants were null and void and that the shares should be returned to the Company. Additionally, the Company sought financial compensation from the counter defendants for financial damage caused as a result of their actions. For the purpose of the trial charge only, the Company capped the requested compensation against counter defendants at NIS 10 million.

On September 5, 2017, the court rendered a judgment in the case (the “Judgement”), under which the complaint against the Company was accepted, the complaint against the CEO Mr. Ronen Luzon was rejected and the Company’s counter-claim was rejected.

The Judgment included: (1) A declaratory remedy, under which the Company breached its contractual undertakings toward the plaintiffs, to list their shares both on the Tel Aviv Stock Exchange and on NASDAQ; (2) An order that the Company take any and all actions required for the listing of the plaintiffs shares, including instructing the Company’s transfer agent to remove the legend or any other restriction from the plaintiffs stock certificate and to issue them with new stock certificates free and clear from any restriction; (3) An order that the registration company of Bank Hapoalim electronically list all of the plaintiffs’ shares detailed in the complaint on the electronic trading system; (iv) The rejection of the complaint against the Company’s CEO, Mr. Luzon, and (4) An order that the Company pay the plaintiffs costs in the amount of NIS 70,000 (which amount is linked to the Israeli CPI and bearing legal interest from the Judgement date until actual payment if effected). Other than the payment of costs the Judgment bears no financial liability on the Company. On October 3 2017, the Company appealed the Judgment with the Supreme Court of Israel, and simultaneously, filed with the Supreme Court a Motion for Stay of Execution of the Judgement, pending the outcome of the appeal.

On October 19, 2017, the respondents filed their response to the Motion and on November 2, 2017 the Company filed its reply the respondents’ response. On November 8, 2017, the Supreme Court upheld the Motion to Stay and ordered that the execution of the Judgment will be stayed pending the outcome of the Appeal, provided that the Company will deposit in the Court’s treasury an autonomous Israeli CPI linked bank guarantee in an amount of NIS 1,700,000, to cover the respondents’ potential damages should the appeal be ultimately denied.

The Company received advice from its legal counsel that the burden of proof that the Judgment is wrong and should be reversed lies with the appellant. Consequently, the Company believes that it is more likely that the appeal will be denied rather than being accepted. In the event that the appeal is the Appeal will be denied, no direct financial liability will be imposed on the Company (other than legal costs which the court may order the losing side to pay).

●

On May 3, 2017, Lightcom (Israel) Ltd., an Israeli company, alleging that it is a shareholder of the Company, filed a motion with the Tel Aviv District Court (Financial Division) to approve an action against the Company as a shareholders’ class action. The subject matter of the action appears to be a report filed by the Company on April 19, 2017. The Court ordered the Company to respond to the motion by November 15, 2017. The complaint alleges, inter alia, that the Company’s report of April 19, 2017 regarding its engagement with the Israeli Post was false and misleading, and that as a result thereof financial damages have been incurred by two purported classes of shareholders: (i) any shareholder who sold Company’s shares as of April 20, 2017 and until April 27, 2017, with respect to damage directly caused by such sale and (ii) any shareholder which held shares on April 20, 2017 and subsequent to April 27, 2017 with respect to damage caused by permanent adverse effect to the shares’ value. The alleged financial damage caused to members of both classes is estimated at NIS 18.8 million. The Company reviewed the motion with its legal counsel and retained an expert to review and analyze the allegations and data upon which the Motion is based. The Company’s management, after considering the conclusions of a report issued by a third party expert and an opinion of U.S. legal counsel, is of the opinion that that the chances that the Class Motion will be denied exceed the risk that it will be approved. In the event that the Class Motion is approved, the complaint will become a class action which will be heard by the Court on its merits. Should this occur,the Company will respond to the Class Motion in the time frame ordered by the Court.

Item 1A. Risk Factors.

Not required for a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On August 16, 2017, the Company entered into a securities purchase agreement (the “SPA”) with two investors. Pursuant to the SPA, the Company sold an aggregate of 250,000 shares of common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $1.00 per share to one investor.

On August 16, 2017, the Company entered into a securities purchase agreement (the “Installment SPA”) with an investor pursuant to which the investor will purchase $530,000 shares of the Company’s Common Stock at $1.00 per share in separate installments.

In connection with the foregoing, the Company relied upon the exemption from securities registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit Number		Description of Exhibits
31.1*		Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**		XBRL Instance Document
101.SCH**		XBRL Taxonomy Schema
101.CAL**		XBRL Taxonomy Calculation Linkbase
101.DEF**		XBRL Taxonomy Definition Linkbase
101.LAB**		XBRL Taxonomy Label Linkbase
101.PRE**		XBRL Taxonomy Presentation Linkbase

* Filed herewith.

** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	My Size, Inc.

Date: November 13, 2017	By:	/s/ Ronen Luzon
		Ronen Luzon
		Chief Executive Officer (Principal Executive Officer)

Date: November 13, 2017

By:

/s/ Or Kles

Or Kles

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-31.1 2 f10q0917ex31-1_mysizeinc.htm CERTIFICATION

EXHIBIT 31.1

CERTIFICATION

I, Ronen Luzon, certify that:

1. I have reviewed this quarterly report on Form 10-Q of My Size, Inc. for the quarter ended September 30, 2017;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	November 13, 2017

	/s/ Ronen Luzon
	Ronen Luzon
	Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 f10q0917ex31-2_mysizeinc.htm CERTIFICATION

EXHIBIT 31.2

CERTIFICATION

I, Or Kles, certify that:

1. I have reviewed this quarterly report on Form 10-Q of My Size, Inc. for the quarter ended September 30, 2017;

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	November 13, 2017

	/s/ Or Kles
	Or Kles
	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EX-32.1 4 f10q0917ex32-1_mysizeinc.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of My Size, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers, does hereby certify, pursuant to 18 U.S.C. section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	November 13, 2017

	/s/ Ronen Luzon
	Ronen Luzon
	Chief Executive Officer (Principal Executive Officer)

	November 13, 2017

	/s/ Or Kles
	Or Kles
	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EX-101.INS 5 mysz-20170930.xml XBRL INSTANCE FILE 0001211805 2015-12-31 0001211805 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001211805 us-gaap:RetainedEarningsMember 2015-12-31 0001211805 mysz:AvailableForSaleReserveMember 2015-12-31 0001211805 us-gaap:CommonStockMember 2015-12-31 0001211805 us-gaap:ForeignCurrencyGainLossMember 2015-12-31 0001211805 2016-03-31 0001211805 2016-06-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0001211805 us-gaap:RetainedEarningsMember 2016-06-30 0001211805 mysz:AvailableForSaleReserveMember 2016-06-30 0001211805 us-gaap:CommonStockMember 2016-06-30 0001211805 us-gaap:ForeignCurrencyGainLossMember 2016-06-30 0001211805 2016-07-01 2016-09-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2016-07-01 2016-09-30 0001211805 us-gaap:RetainedEarningsMember 2016-07-01 2016-09-30 0001211805 mysz:AvailableForSaleReserveMember 2016-07-01 2016-09-30 0001211805 us-gaap:CommonStockMember 2016-07-01 2016-09-30 0001211805 us-gaap:ForeignCurrencyGainLossMember 2016-07-01 2016-09-30 0001211805 mysz:EquityAwardsMember 2016-07-01 2016-09-30 0001211805 mysz:LiabilityAwardsMember 2016-07-01 2016-09-30 0001211805 2016-01-01 2016-09-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001211805 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0001211805 mysz:AvailableForSaleReserveMember 2016-01-01 2016-09-30 0001211805 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001211805 us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-09-30 0001211805 mysz:EquityAwardsMember 2016-01-01 2016-09-30 0001211805 mysz:LiabilityAwardsMember 2016-01-01 2016-09-30 0001211805 2016-09-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001211805 us-gaap:RetainedEarningsMember 2016-09-30 0001211805 mysz:AvailableForSaleReserveMember 2016-09-30 0001211805 us-gaap:CommonStockMember 2016-09-30 0001211805 us-gaap:ForeignCurrencyGainLossMember 2016-09-30 0001211805 2016-01-01 2016-12-31 0001211805 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001211805 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001211805 mysz:AvailableForSaleReserveMember 2016-01-01 2016-12-31 0001211805 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001211805 us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-12-31 0001211805 mysz:EquityAwardsMember 2016-01-01 2016-12-31 0001211805 mysz:LiabilityAwardsMember 2016-01-01 2016-12-31 0001211805 mysz:ConsultantMember 2016-01-01 2016-12-31 0001211805 mysz:FiveInstallmentMember 2016-01-01 2016-12-31 0001211805 mysz:SixthInstallmentMember 2016-01-01 2016-12-31 0001211805 mysz:ConsultantTwoMember 2016-01-01 2016-12-31 0001211805 mysz:ConsultantTwoMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0001211805 mysz:ConsultantTwoMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0001211805 2016-12-31 0001211805 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001211805 us-gaap:RetainedEarningsMember 2016-12-31 0001211805 mysz:AvailableForSaleReserveMember 2016-12-31 0001211805 us-gaap:CommonStockMember 2016-12-31 0001211805 us-gaap:ForeignCurrencyGainLossMember 2016-12-31 0001211805 mysz:ConsultantMember 2016-12-31 0001211805 us-gaap:FairValueInputsLevel1Member 2016-12-31 0001211805 us-gaap:FairValueInputsLevel2Member 2016-12-31 0001211805 us-gaap:FairValueInputsLevel3Member 2016-12-31 0001211805 2017-02-28 0001211805 2017-02-01 2017-02-28 0001211805 2017-03-31 0001211805 2017-04-01 2017-04-27 0001211805 mysz:FinancialConsultantMember 2017-04-03 2017-04-30 0001211805 mysz:ConsultantTwoMember us-gaap:MaximumMember 2017-05-16 0001211805 mysz:ConsultantTwoMember us-gaap:MinimumMember 2017-05-16 0001211805 mysz:ListingQualificationsDepartmentMember 2017-06-01 2017-06-05 0001211805 2017-06-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001211805 us-gaap:RetainedEarningsMember 2017-06-30 0001211805 mysz:AvailableForSaleReserveMember 2017-06-30 0001211805 us-gaap:CommonStockMember 2017-06-30 0001211805 us-gaap:ForeignCurrencyGainLossMember 2017-06-30 0001211805 us-gaap:BoardOfDirectorsChairmanMember 2017-08-16 0001211805 2017-09-26 0001211805 2017-09-02 2017-09-26 0001211805 2017-07-01 2017-09-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2017-07-01 2017-09-30 0001211805 us-gaap:RetainedEarningsMember 2017-07-01 2017-09-30 0001211805 mysz:AvailableForSaleReserveMember 2017-07-01 2017-09-30 0001211805 us-gaap:CommonStockMember 2017-07-01 2017-09-30 0001211805 us-gaap:ForeignCurrencyGainLossMember 2017-07-01 2017-09-30 0001211805 mysz:EquityAwardsMember 2017-07-01 2017-09-30 0001211805 mysz:LiabilityAwardsMember 2017-07-01 2017-09-30 0001211805 2017-01-01 2017-09-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0001211805 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0001211805 mysz:AvailableForSaleReserveMember 2017-01-01 2017-09-30 0001211805 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001211805 us-gaap:ForeignCurrencyGainLossMember 2017-01-01 2017-09-30 0001211805 mysz:EquityAwardsMember 2017-01-01 2017-09-30 0001211805 mysz:LiabilityAwardsMember 2017-01-01 2017-09-30 0001211805 mysz:FinancialConsultantMember 2017-01-01 2017-09-30 0001211805 mysz:DefendantsMember 2017-01-01 2017-09-30 0001211805 2017-09-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001211805 us-gaap:RetainedEarningsMember 2017-09-30 0001211805 mysz:AvailableForSaleReserveMember 2017-09-30 0001211805 us-gaap:CommonStockMember 2017-09-30 0001211805 us-gaap:ForeignCurrencyGainLossMember 2017-09-30 0001211805 us-gaap:FairValueInputsLevel1Member 2017-09-30 0001211805 us-gaap:FairValueInputsLevel2Member 2017-09-30 0001211805 us-gaap:FairValueInputsLevel3Member 2017-09-30 0001211805 us-gaap:BoardOfDirectorsChairmanMember 2017-09-30 0001211805 us-gaap:PaymentGuaranteeMember 2017-09-30 0001211805 mysz:FundRaisingAgreementMember 2017-09-30 0001211805 us-gaap:SubsequentEventMember 2017-10-01 2017-10-26 0001211805 2017-11-12 0001211805 us-gaap:SubsequentEventMember 2018-03-31 0001211805 us-gaap:SubsequentEventMember 2018-03-01 2018-03-31 xbrli:shares iso4217:USD iso4217:USDxbrli:shares iso4217:CNY iso4217:ILSxbrli:shares xbrli:pure iso4217:ILS My Size, Inc. 0001211805 MYSZ false --12-31 10-Q 2017-09-30 2017 Q3 Smaller Reporting Company 18394817

919000

425000

98000

143000

34000

359000

128000

14000

1401000

304000

62000

69000

1497000

387000

579000

246000

74000

67000

653000

313000

2150000

700000

229000

315000

316000

442000

80000

435000

136000

625000

1192000

17000

18000

13347000

14740000

-93000

-102000

-87000

-11644000

-15163000

-2613000

4853000

-7310000

-67000

15000

-104000

804000

11155000

-10706000

527000

15000

-187000

1023000

12589000

-11430000

17000

-153000

1525000

13347000

-11644000

-93000

17000

-102000

-457000

14052000

-14356000

-67000

17000

-103000

-492000

14740000

-15163000

18000

-87000

2150000

700000

0.001

50000000

17405359

18078218

17405359

18078218

172000

500000

727000

213000

624000

434000

1359000

1859000

611000

2667000

606000

1859000

2586000

824000

3291000

-606000

-1859000

-2586000

-824000

-3291000

-118000

-2261000

-1748000

17000

-228000

-724000

-4120000

-4334000

-807000

-3519000

527000

-67000

24000

-67000

-93000

35000

-49000

2000

16000

15000

-1216000

-724000

-527000

34000

-4102000

-4120000

67000

-49000

-4356000

-4334000

-24000

2000

-724000

-807000

67000

16000

-3411000

-3519000

93000

15000

-0.04

-0.26

-0.27

-0.04

-0.19

16584354

15741967

16345499

17625440

17599340

15313793

17405359

17605359

18078218

-39000

-33000

-23000

53000

126000

1041000 1041000 987000 987000 60000 60000 60000 60000 80359 80359

576000

575000

1000

1208000

1207000

1000

392500

1208

592500

1475000

1473000

2000

6730000

6728000

2000

7530000

7528000

2000

2091566

6000

17000

24000

7000

22000

117000

2260000

-182000

-101000

-251000

-776000 1233000 132000 472000

-39000

-33000

-23000

53000

126000

88000 265000

39000

43000

27000

-61000

-115000

-80000

27000

-126000

-62000

44000

86000

127000

64000

57000

127000

208000

-60000

108000

-684000

-1748000

-2159000

-527000

-2472000

8000

31000

36000

1000

8000

-8000

-31000

-36000

-1000

-8000

25000

10000

739000 1043000 1339000 491000 2506000

739000

1018000

1314000

491000

2496000

-2000

-15000

-4000

-77000

-36000

45000

-776000

-885000

-114000

-20000

987000 987000

4939000

4846000

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Note 1 - General<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px;"> </td><td style="width: 24px;">a.</td><td>My Size Inc. (the “Company”), is a dual listed publicly traded company whose common stock is publicly trading on the TASE since September 2005 (under the name Topspin Medical Inc) and on the NASDAQ Capital Market (“NASDAQ”) since July 25, 2016. The Company has developed a measurement technology based on algorithms with broad applications in a variety of areas, from the apparel e-commerce market to Do It Yourself (“DIY”) smartphone and tablet apps. The technology is driven by several patent-pending algorithms which are able to calculate and record measurements in a variety of novel ways. Since February 2014, the Company also operates via a wholly-owned subsidiary, My Size (Israel) 2014 Ltd., a company registered in Israel.</td></tr><tr style="vertical-align: top;"><td> </td><td> </td><td style="text-align: justify;"> </td></tr><tr style="vertical-align: top;"><td> </td><td>b.</td><td style="text-align: justify;">Since inception, the Company has incurred losses and negative cash flows from operations, and as of the date of the report has an accumulated loss amounting to approximately $15.1 million. The Company has financed its operations mainly through fundraising from private investors.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of September 30, 2017, the Company entered into agreements pursuant to which it raised an aggregate of $8,795 of which $5,753 and $1,410 were received in cash and marketable securities, respectively. The marketable securities are shares of common stock of Diamante Minerals Inc (“DIMN”), which are accounted as a financial asset available for sale and presented in the Company’s balance sheet under investment in marketable securities. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 56.7pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of September 30, 2017, the Company has $1,177 and $455 in guaranteed notes and checks, respectively as remaining balance from the amounts described above. The guarantee has been provided by an ungraded financial institution. Subsequent to September 30, 2017, $236 of the guarantee notes have been redeemed in cash.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 54pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 54pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Based on the projected cash flows and cash balances as of September 30, 2017, the Company’s Management is of the opinion that without further fund raising it will not have sufficient resources to enable it to continue its operating activities including the development, and marketing of its products for a period of at least 12 months from the date of approval of these financial statements. As a result, there is substantial doubt about the Company’s ability to continue as a going concern.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 54pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 54pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Management’s plans include the continued commercialization of the Company’s products and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships, see also note 7. There can be no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to cease operations.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern.</div>

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 56.7pt; text-align: justify; color: #000000; text-transform: none; text-indent: -56.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Note 3 - Financial Instruments<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Fair value of financial instruments:<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">ASC 820, “Fair Value Measurements and Disclosures”, defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 58px; font-stretch: normal;">Level 1 -</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 2 -</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Level 3 -</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 141.75pt; text-align: justify; color: #000000; text-transform: none; text-indent: -56.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The carrying amounts of cash and cash equivalents, other accounts receivable, accounts payable and other accounts payable approximate their fair value due to the short-term maturities of such instruments.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company holds shares in a publicly-traded company - Diamante Minerals, Inc. which are classified as available-for-sale equity securities. The marketable securities have readily determinable fair market values that are calculated based on the share price on the measurement date and ranked as Level 1 assets. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">September 30, 2017</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">Fair value hierarchy</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 1</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 2</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 3</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Financial assets</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;">Investment in marketable securities</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">246</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">    -</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">    -</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 85.05pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">September 30, 2017</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">Fair value hierarchy</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 1</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 2</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 3</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;">Financial liabilities</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;">Derivative liabilities</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">     -</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">299</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">    -</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Warrants and share based liabilities</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">136</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 56.7pt; text-align: justify; color: #000000; text-transform: none; text-indent: -56.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">December 31, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">Fair value hierarchy</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 1</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 2</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 3</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Financial assets</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;">Investment in marketable securities</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">579</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">     -</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">     -</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">December 31, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">Fair value hierarchy</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 1</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 2</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 3</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Financial liabilities</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;">Derivative liabilities</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">       -</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">80</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">      -</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 85.05pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At September 30, 2017, the fair value (based on quoted market prices) of these securities was $246. During the nine month period ended September 30, 2017 the recognized loss was $472 (At December 31, 2016, gross unrecognized loss, recognized loss and fair value (based on quoted market prices) of these securities were $24, $1,233 and $579, respectively).</div>

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 56.7pt; text-align: justify; color: #000000; text-transform: none; text-indent: -56.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Note 4 - Stock Based Compensation<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 56.7pt; text-align: justify; color: #000000; text-transform: none; text-indent: -56.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The stock based expense (income) recognized in the financial statements for services received from non-employees is related to Marketing, General and Administrative expenses and shown in the following table: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: -10pt; padding-left: 10pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="6">Nine months ended  September 30,</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="6">Three months ended  September 30,</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-size-adjust: none; font-stretch: normal;" colspan="2">Year ended December 31,</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: -10pt; padding-left: 10pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">2017</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">2017</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-size-adjust: none; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;">Stock-based compensation expense - equity awards</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;">126</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;">(33</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;">) </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;">53</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;">(39</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;">) </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;">(23</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;">)</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-size-adjust: none; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt; font-size-adjust: none; font-stretch: normal;">Stock-based compensation expense - liability awards</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">265</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">88</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal; background-color: #cceeff;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-size-adjust: none; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 4pt; padding-left: 10pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">391</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">(33</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">) </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">141</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">(39</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">(23</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">)</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 85.05pt; text-align: justify; color: #000000; text-transform: none; text-indent: -28.35pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 85.05pt; text-align: justify; color: #000000; text-transform: none; text-indent: -28.35pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px; font-size: 10pt;"> </td><td style="width: 24px; font-size: 10pt;">a.</td><td>In December 2016, the Company entered into a consulting agreement with a consultant ( “Consultant1”) pursuant to which Consultant1 is providing services in connection with marketing strategies, micro and macro-economic issues and for the promotion of the Company’s marketing, business, products and operations through smartphone applications. The agreement is for a period of 18 months commencing October 2016. In consideration for services provided under the consulting agreement, the Company agreed to issue Consultant1 25,000 shares of common stock of the Company which are to be issued over six quarters as follows: 4,150 issued over each of the first five quarters and a sixth installment of 4,250 to be issued on the sixth quarter of the consulting agreement. In addition, the Company has agreed to issue to Consultant1 stock options to purchase up to 40,000 shares of the Company’s common stock, exercisable not later than March 31, 2018 at an exercise price of NIS18 per share.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 85.05pt; text-align: justify; color: #000000; text-transform: none; text-indent: -28.35pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In addition, the Company undertook to pay the balance of the consideration for the sale of the shares by Consultant1 up to the sum of NIS500,000. If the consideration for the sale of the shares falls below 90% of the shares’ price on the stock exchange on the date of sale, the Company shall pay Consultant1 the difference. The Company may decide at its own discretion whether to make such payment in cash or shares of common stock.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">On March 21, 2017, the shareholders of the Company approved the adoption of the 2017 Consultant Equity Incentive Plan at the Company’s Annual Meeting of Stockholders. The approval was required for the issuance of the options and shares of common stock of the Company issued to Consultant1.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">During the nine-month period ended September 30, 2017, costs in the sum of $(4) ($90 during 2016) were recorded by the Company and an undertaking to pay the balance of the consideration was recognized in the sum of $124 ($80 during 2016) according to the fair value of the undertaking.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px; font-size: 10pt;"> </td><td style="width: 24px; font-size: 10pt;">b.</td><td>In December 2016, the Company engaged a consultant (“Consultant2”) to provide services to the Company with respect to marketing strategy and public relations, including potential investors relations. For such consulting services, the Company agreed to issue to Consultant2 options to purchase up to 2,000,000 shares of the Company’s common stock at variable exercise prices ranging from $3.50 to $9.00 per share. The options are exercisable for periods ranging from 12 months (or 6 months from filing date of registration statement) to 36 months. The issuance of the options under the agreement was subject to the receipt of all the approvals required by the laws applicable to the Company, including stock exchange approvals and the approval by the Company’s shareholders to adopt an equity incentive plan for consultants. The equity incentive plan for consultants was approved by the shareholders on March 21, 2017 at the Company’s Annual Meeting of Stockholders. On May 16, 2017, the Company and the Consultant2 entered into an amendment to the consulting agreement pursuant to which the strike prices of the options were amended to a range from $1.50 to $5.00 per share. Following initial grant, the Company reclassified the options from equity accounted under ASC 505-50 to derivative liability accounted under ASC 815. The expense recognize in the second and third quarters, including the cost associates with the consulting service attributed to the reporting period and the revaluation of the derivative amounted to $186. An amount of $88 and $27 was recorded in the balance sheet as warrants and share based liabilities and share based payments respectively. </td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;">c.</td><td>In April 2017, the Company engaged a consultant (“Consultant3”) to provide services to the Company with respect to financing and strategic advisory for a period of two years. For such consulting services, the Company agreed to pay a monthly retainer and to issue to the Consultant3 50,000 shares of the Company common stock and 31,250 shares each quarter thereafter. During the nine-month period ended September 30, 2017, costs in the sum of $76 were recorded by the Company as stock-based compensation expense- equity awards.</td></tr></table></div>

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Note 5 - Contingencies and Commitments<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 110.7pt; text-align: justify; color: #000000; text-transform: none; text-indent: 110.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 110.7pt; text-align: justify; color: #000000; text-transform: none; text-indent: 110.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px; font-size: 10pt;"> </td><td style="width: 24px; font-size: 10pt;">a.</td><td style="text-align: justify; font-size: 10pt;">Further to Note 10a to the Annual Report on Form 10-K for the year ended December 31, 2016:</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 110.7pt; text-align: justify; color: #000000; text-transform: none; text-indent: 110.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On December 27, 2015, the Company received a legal complaint (the “Complaint”). The defendants named in the Complaint were the Company, all the members of the Board of Directors of the Company, the officers of the Company, Mrs. Shoshana Zigdon, a shareholder and related party of the Company, as well as two additional defendants who are not shareholders of the Company. The plaintiff alleged that the Company violated its obligation to register shares purchased by the plaintiff on July 3, 2014 (the “Original Shares”) for trade with the Tel Aviv Stock Exchange.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company and plaintiff entered into a settlement agreement (the “Settlement”) dated June 20, 2017 following a mediation process. Pursuant to the Settlement, the Company agreed to make a payment to the plaintiff of NIS325,000 (the “Down Payment”) within 30 days of the date of the Settlement. Additionally, the Company is obligated to register the Original Shares within a specified time frame. Moreover, pursuant to the Settlement, the Company agreed to issue, within 60 days, 80,358 additional shares of common stock to the plaintiff (the “New Shares”), which New Shares shall be registered, to be deposited in escrow and sold for the benefit of plaintiff. To the extent the Company will not issue the unrestricted New Shares within 60 days of the Settlement, the plaintiff has a right, at his sole discretion, to resume the legal proceedings pursuant to the Complaint, provided he deposits the Down Payment in an escrow account, pending the Court’s final adjudication of the Complaint. Additionally, the Settlement provides that to the extent the aggregate proceeds from the sale of the Original Shares and the New Shares is less than NIS1,600,000, the Company will either complement the difference in cash or shall issue to the plaintiff additional shares of common stock in lieu thereof, at the Company’s sole discretion.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">During the three month period ended September 30 2017, the Company issued shares and recorded an amount of $60 in equity and paid the plaintiff the Down Payment. As of September 30, 2017, The Company recorded a derivative liability in the amount of $176.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 48px; font-size: 10pt;"> </td><td style="width: 24px; font-size: 10pt;">b.</td><td>Further to Note 10b to the Annual Report on Form 10-K for the year ended December 31, 2016., The Company has paid its obligation to the investor in full, As of the date on which the financial statements were signed.</td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td> </td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;">c.</td><td>Further to Note 10c to the annual report on Form 10-K for the year ended December 31, 2016: On September 5, 2017, the Court rendered a judgment in the case (the “Judgment”), under which the complaint against the Company was accepted, the complaint against the CEO Mr. Ronen Luzon was rejected and the Company’s counter-claim was rejected. The Judgment included: (1) A declaratory remedy, under which the Company breached its contractual undertakings toward the plaintiffs, to list their shares both on the Tel Aviv Stock Exchange and on NASDAQ; (2) An Order that the Company take any and all actions required for the listing of the plaintiffs shares, including instructing the Company’s transfer agent to remove the legend or any other restriction from the plaintiffs stock certificate and to issue them with new stock certificates free and clear from any restriction; (3) An order that the registration company of Bank Hapoalim electronically list all of the plaintiffs’ shares detailed in the complaint on the electronic trading system; (iv) A rejection of the complaint against the Company’s CEO Mr. Luzon (4) An order that the Company pay the plaintiffs costs in the amount of NIS 70,000 (which amount is linked to the Israeli CPI and bearing legal interest from the Judgment date until actual payment if effected). Other than the payment of costs the Judgment bears no financial liability on the Company. On October 3 2017 the Company appealed the Judgment with the Supreme Court of Israel and simultaneously, filed with the Supreme Court a Motion for Stay of Execution of the Judgment, pending the outcome of the appeal. On October 19, 2017, the respondents filed their response to the Motion and on November 2, 2017 the Company filed its reply the respondents’ response. On November 8, 2017, the Supreme Court upheld the Motion to Stay and ordered that the execution of the Judgment will be stayed pending the outcome of the Appeal, provided that the Company will deposit in the Court’s treasury an autonomous Israeli CPI linked bank guarantee in an amount of NIS 1,700,000, to cover the respondents’ potential damages should the appeal be ultimately denied. The Company received legal advice from its counsel that the burden of proof that the Judgment is wrong and should be reversed lies with the appellant. Consequently, the Company believes that it is more likely than not that the appeal will be denied rather than being accepted. In the event that the Appeal is denied, no direct financial liability will be imposed on the Company (other than legal costs which the court may order the losing side to pay). </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; font-stretch: normal;">d.</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">On May 3, 2017, Lightcom (Israel) Ltd., an Israeli company, alleging that it is a shareholder of the Company, filed a motion (the “Motion”) with the Tel Aviv District Court (Financial Division) to approve an action against the Company as a shareholders’ class action. The subject matter of the action appears to be a report filed by the Company on April 19, 2017. The Court ordered the Company to respond to the motion by November 15, 2017.  The Motion alleges, inter alia, that the Company’s report date April 19, 2017 regarding its engagement with the Israeli Post was false and misleading, and that as a result thereof financial damages have been incurred by two purported classes of shareholders: (i) any shareholder who sold Company’s shares as of April 20, 2017 and until April 27, 2017, with respect to damage directly caused by such sale and (ii) any shareholder who held shares on April 20, 2017 and subsequent to April 27, 2017 with respect to damage caused by permanent adverse effect to the shares’ value. The alleged financial damage caused to members of both classes is estimated at NIS 18.8 million. The Company reviewed the Motion initially with its legal counsel and retained an expert to review and analyze the allegations and data upon which the Motion is based. The Company’s management, after considering the conclusions of a report issued by a third party expert and an opinion of U.S. legal counsel, is of the opinion that the chances that the Class Motion will be denied exceed the risk that it will be approved. In the event that the Class Motion will be approved, the complaint will become a class action which will be heard by the Court on its merits. Should this occur, the Company will respond to the Class Motion in the time frame ordered by the Court.</td></tr></table></div>

<div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Note 6 - Significant Events During the Reporting Period <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 74.7pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 48px;"> </td> <td style="width: 24px;">a.</td> <td style="text-align: justify;">In February 2017, the Board of Directors approved agreements with investors that will provide an investment for a total amount of $200 in exchange for 200,000 shares of common stock of the Company. In addition, the Company will issue warrants exercisable for an aggregate of 250,000 shares of common stock of the Company until December 22, 2017 at an exercise price of $3.50 per share.</td> </tr> <tr style="vertical-align: top;"> <td> </td> <td> </td> <td style="text-align: justify;"> </td> </tr> <tr style="vertical-align: top;"> <td> </td> <td>b.</td> <td style="text-align: justify;">On June 5, 2017, the Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC notifying the Company that for the preceding 30 consecutive business days, the Company’s common stock did not maintain a minimum Market Value of Listed Securities of $35 million (“MVLS Requirement”) per share as required by NASDAQ Listing Rule 5550(b)(2).</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 74.7pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In accordance with NASDAQ Listing Rule 5810(c)(3)(C), the Company has a grace period of 180 calendar days, or until December 4, 2017, to regain compliance with NASDAQ Listing Rule 5550(b)(2). The Company will endeavor to rectify the situation and to meet the MVLS Requirement. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 48px; font-size: 10pt;"> </td> <td style="width: 24px; text-align: justify; font-size: 10pt;">c.</td> <td style="text-align: justify; font-size: 10pt;">On August 16 2017, the Board of Directors approved agreements with three private investors who will provide investment totaling $780 in exchange for 780,000 shares of common stock of the Company.</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 1in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 54pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 54pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During August and September 2017, the Company received $341 from the investments in cash. The remaining amount of the investment is guaranteed by notes. Subsequent to September 30 2017, $236 was received in cash. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 54pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 54pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="text-align: left; vertical-align: top;"> <td style="width: 48px;"> </td> <td style="width: 24px;">d.</td> <td style="text-align: justify;">On September 26, 2017, the Company was notified (the “Notification Letter”) by The NASDAQ Stock Market, LLC (“NASDAQ”) that it is not in compliance with the minimum bid price requirements set forth in NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and NASDAQ Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on The NASDAQ Capital Market and, at this time, the common stock will continue to trade on The NASDAQ Capital Market under the symbol “MYSZ”.</td> </tr> <tr style="text-align: left; vertical-align: top;"> <td> </td> <td> </td> <td style="text-align: justify;"> </td> </tr> <tr style="text-align: left; vertical-align: top;"> <td> </td> <td> </td> <td style="text-align: justify;"> <p style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; margin-top: 0pt; margin-right: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal; background-color: white;">The Notification Letter provides that the Company has 180 calendar days, or until March 26, 2018, to regain compliance with NASDAQ Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by March 26, 2018, an additional 180 days may be granted to regain compliance, so long as the Company meets The NASDAQ Capital Market continued listing requirements (except for the bid price requirement) and notifies  NASDAQ in writing of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then NASDAQ will notify the Company of its determination to delist the Company's common stock, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel. </td> </tr> <tr style="text-align: left; vertical-align: top;"> <td> </td> <td> </td> <td style="text-align: justify;"> </td> </tr> <tr style="text-align: left; vertical-align: top;"> <td> </td> <td> </td> <td style="text-align: justify;"> <p style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; margin-top: 0pt; margin-right: 0px; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal; background-color: white;">The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the minimum bid price requirement under the NASDAQ Listing Rules. </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 54pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  </div>

<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 24px; font-stretch: normal;">a.</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Unaudited condensed consolidated interim financial statements:</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The accompanying unaudited condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The unaudited condensed consolidated financial statements are comprised of the financial statements of the Company and its subsidiaries collectively referred to as the Company. In management’s opinion, the interim financial data presented includes all adjustments necessary for a fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles (“GAAP”) has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2017.<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">These unaudited condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2016.

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.75in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">September 30, 2017</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">Fair value hierarchy</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 1</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 2</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 3</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;">Financial assets</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;">Investment in marketable securities</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">246</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">    -</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">    -</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 85.05pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">September 30, 2017</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">Fair value hierarchy</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 1</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 2</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 3</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;">Derivative liabilities</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">     -</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">299</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">    -</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Warrants and share based liabilities</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">136</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 56.7pt; text-align: justify; color: #000000; text-transform: none; text-indent: -56.7pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">December 31, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">Fair value hierarchy</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 1</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 2</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 3</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Financial assets</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;">Investment in marketable securities</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">579</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">     -</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">     -</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">December 31, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="10">Fair value hierarchy</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 1</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 2</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Level 3</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Financial liabilities</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;">Derivative liabilities</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">       -</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">80</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;">      -</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td></tr></table>

<div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: -10pt; padding-left: 10pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">Nine months ended  September 30,</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">Three months ended  September 30,</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;" colspan="2">Year ended December 31,</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: -10pt; padding-left: 10pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2017</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2017</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;" colspan="2"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 48px; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt; font-stretch: normal; background-color: #cceeff;">Stock-based compensation expense - equity awards</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">126</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">(33</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;">) </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">53</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">(39</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;">) </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal; background-color: #cceeff;">(23</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal; background-color: #cceeff;">)</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt; font-stretch: normal;">Stock-based compensation expense - liability awards</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">265</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">88</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-left: 10pt; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal; background-color: #cceeff;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: #cceeff;"> </td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -10pt; padding-bottom: 4pt; padding-left: 10pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">391</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(33</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">) </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">141</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(39</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(23</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">)</td></tr></table></div>

15100000

5753000

8795000

1410000

1177000 455000

579000

246000

80000

299000

24000

1233000

472000

579000

246000

-39000

-33000

-23000

141000

53000

88000

391000

126000

265000

500000 500000

25000

4150

4250

90000 -4000

80000

124000

2000000 9.00 3.50

<div>The Company agreed to issue to Consultant2 options to purchase up to 2,000,000 shares of the Company’s common stock at variable exercise prices ranging from $3.50 to $9.00 per share. The options are exercisable for periods ranging from 12 months (or 6 months from filing date of registration statement) to 36 months.</div>

186000

5.00

1.50

0.90 P18M

88000

27000

40000

<div>The Company agreed to pay a monthly retainer and to issue to the Consultant3 50,000 shares of the Company common stock and 31,250 shares each quarter thereafter.</div>

76000

18800000

The Company agreed to issue, within 60 days, 80,358 additional shares of common stock to the plaintiff (the “New Shares”), which New Shares shall be registered, to be deposited in escrow and sold for the benefit of plaintiff. To the extent the Company will not issue the unrestricted New Shares within 60 days of the Settlement, the plaintiff has a right, at his sole discretion, to resume the legal proceedings pursuant to the Complaint, provided he deposits the Down Payment in an escrow account, pending the Court’s final adjudication of the Complaint. Additionally, the Settlement provides that to the extent the aggregate proceeds from the sale of the Original Shares and the New Shares is less than NIS1,600,000, the Company will either complement the difference in cash or shall issue to the plaintiff additional shares of common stock in lieu thereof, at the Company’s sole discretion.

The Company and plaintiff entered into a settlement agreement (the “Settlement”) dated June 20, 2017 following a mediation process. Pursuant to the Settlement, the Company agreed to make a payment to the plaintiff of NIS325,000 (the “Down Payment”) within 30 days of the date of the Settlement. Additionally, the Company is obligated to register the Original Shares within a specified time frame. Moreover, pursuant to the Settlement.

1700000000 91000

70000

60000

176000

60000

200000

250000

3.50

2017-12-22 <div>The Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC notifying the Company that for the preceding 30 consecutive business days, the Company’s common stock did not maintain a minimum Market Value of Listed Securities of $35 million (“MVLS Requirement”) per share as required by NASDAQ Listing Rule 5550(b)(2).</div> The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and NASDAQ Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company no longer meets the minimum bid price requirement.

341000

236000

780000

0.75

<div>My Size, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) to sell original issue discount non-convertible notes (the “Notes”) and warrants (the “Warrants”) to certain accredited investors in a private placement transaction (the “Offering”). In connection with the Offering, the Company issued (i) Notes with a principal amount of $1.33 million and (ii) 888,888 Warrants. The Offering resulted in gross proceeds to the Company of approximately $1.2 million, before deducting placement agent and other offering expenses.</div>

P5Y Less than $1.

EX-101.SCH 6 mysz-20170930.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Interim Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Interim Statements of Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Consolidated Interim Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - General link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Financial Instruments link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Stock Based Compensation link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Contingencies and Commitments link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Significant Events During the Reporting Period link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Financial Instruments (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Stock Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - General (Details) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Financial Instruments (Details) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Financial Instruments (Details Textual) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Stock Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Stock Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Contingencies and Commitments (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Significant Events During the Reporting Period (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Subsequent Events (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 mysz-20170930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 mysz-20170930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 mysz-20170930_lab.xml XBRL LABEL FILE Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Trading Symbol Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Filer Category Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Assets [Abstract] Assets Assets, Current [Abstract] Current Assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Prepaid Expense and Other Assets, Current Other receivables and prepaid expenses Total other accounts receivables Restricted Cash and Cash Equivalents, Current Restricted cash Assets, Current, Total Total current assets Marketable Securities, Noncurrent Investment in marketable securities Property, Plant and Equipment, Net Property and equipment net, carrying amounts Property and equipment, net Property and equipment net, carrying amounts Total non current Total noncurrent assets Assets, Total Assets ASSETS Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities Accounts Payable, Trade, Current Trade payable Accounts Payable, Current Accounts payable Warrants and share based liabilities Warrants, Derivative and share based liabilities Liabilities, Current, Total Total current liabilities Commitments and Contingencies COMMITMENTS AND CONTINGENCIES Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity (Deficit): Common Stock, Value, Issued Common stock of $ 0.001 par value - Authorized: 50,000,000 shares; Issued and outstanding: 18,078,218 and 17,405,359 As of September 30, 2017 and December 31, 2016, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Available For Sale Reserve Available for sale reserve Available for sale reserve. Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit), Total Accumulated deficit Stockholders' Equity Attributable to Parent Stockholders' equity Total stockholders' equity (Deficit) Balance Balance Liabilities and Equity, Total TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Total liabilities and stockholders' equity Total liabilities and stockholders' equity Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Income Statement [Abstract] Operating Expenses [Abstract] Operating expenses Operating expenses: Research and Development Expense, Total Research and development Research and development Other General and Administrative Expense Marketing, General and administrative Marketing, General and administrative Marketing, general and administrative Operating Expenses, Total Total operating expenses Total operating expenses Operating Income (Loss), Total Operating loss Gain (Loss) on Investments, Total Financial (expenses) income, net Net Income (Loss) Attributable to Parent Net income Net income (loss) Loss before income taxes Net loss from continuing operations Net loss Loss before income taxes Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract] Other comprehensive loss: Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax Gain (loss) on available for sale securities Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Foreign currency translation differences Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total Total comprehensive loss Total comprehensive loss Earnings Per Share, Basic and Diluted Basic and diluted loss per share Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted weighted average number of shares outstanding Statement of Stockholders' Equity [Abstract] Statement [Table] Income Statement Location [Axis] Income Statement Location [Domain] Foreign Currency Gain (Loss) [Member] Foreign currency transaction Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common stock Additional Paid-in Capital [Member] Additional paid-in capital Available For Sale Reserve [Member] Available for sale reserve Retained Earnings [Member] Accumulated Deficit AOCI Attributable to Parent [Member] Accumulated other comprehensive income (loss) Statement [Line Items] Shares, Outstanding Balance, shares Balance, shares Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Stock-based compensation related to options granted to consultants Warrants Converted And Exercised Equity Value Warrants converted and exercised into equity Warrants converted and exercised into equity value. Warrants Converted And Exercised Equity Shares Warrants converted and exercised into equity shares. Warrants converted and exercised into equity, shares Stock Issued During Period, Value, Other Issuance and receipts on account of shares Stock Issued During Period, Shares, Other Issuance and receipts on account of shares, shares Stock Issued During Period, Value, Conversion of Convertible Securities Convertible loans converted to equity Marketable Securities, Gain (Loss) Gain on marketable securities Stock Issued During Period, Shares, Conversion of Convertible Securities Convertible issued shares Convertible loans converted to equity, shares Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Total Depreciation Amortization of Debt Issuance Costs and Discounts Amortization of warrant, convertible loans and derivative Revaluation Put Option Revaluation PUT Option Revaluation PUT Option. Revaluation of PUT options Revaluation Investment In Marketable Securities Revaluation of investment in marketable securities Revaluation investment in marketable securities. Share-based Compensation Sum of cost Stock based compensation- equity Stock Based Compensation Liability Stock based compensation- liability The aggregate amount liability of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. Increase (Decrease) in Other Receivables Decrease (increase) in receivables and prepaid expenses Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Increase in Embedded Derivative Increase in derivative liabilities Increase (Decrease) in Accounts Payable, Trade Increase (decrease) in trade payable Increase (Decrease) in Other Accounts Payable Increase (decrease) in other accounts payable Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations, Total Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Payments for Loans Payment for a loan Repayment of a loan Issuing Financial Package Proceeds from issuance of shares, warrants and convertible loans Amount of issuing financial package. Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total Net cash provided by financing activities Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations Effect of exchange rate changes on cash and cash equivalents Effect of exchange rate changes on cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease), Total Increase (Decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Non cash transactions Warrants Reclassified To Equity As Result Of Amended Exercise Price Currency1 Warrants reclassified to equity as a result of amended exercise price currency Warrants reclassified to equity result of amended exercise price currency. Debt Conversion, Converted Instrument, Amount Conversion of loan to equity General [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] General Significant Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Significant Accounting Policies Financial Instruments [Abstract] Financial Instruments (Abstract) Fair Value Disclosures [Text Block] Financial Instruments Stock Based Compensation [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Based Compensation Contingencies and Commitments [Abstract] Commitments and Contingencies Disclosure [Text Block] Contingencies and Commitments Significant Events During the Reporting Period [Abstract] Significant events during reporting period. Significant Events During Reporting Period [Text Block] Significant Events During the Reporting Period Significant events during reporting period. Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events Consolidation, Policy [Policy Text Block] Unaudited condensed consolidated financial statements: Use of Estimates, Policy [Policy Text Block] Use of estimates: Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block] Schedule of significant assets and liabilities that are measured at fair value on recurring basis Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summary of stock based expense (income) recognized for services received from non-employees General [Table] Agreement [Axis] Agreement [Domain] Fund Raising Agreement [Member] Fund raising agreements [Member] Fund raising agreement. Scenario [Axis] Scenario, Unspecified [Domain] Subsequent To September Thirty Two Zero One Seven [Member] Subsequent to September 30, 2017 [Member] Title of Individual [Axis] Relationship to Entity [Domain] Director [Member] Board of Directors [Member] Directors [Member] Directors [Member] Guarantor Obligations, Nature [Axis] Guarantor Obligations, Nature [Domain] Payment Guarantee [Member] Guarantee notes [Member] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Events [Member] Subsequent Event [Member] General [Line Items] General Textual [Abstract] General (Textual) Goodwill, Impaired, Accumulated Impairment Loss Accumulated loss Cash Cash Cash Funds Net Aggregate raised, amount Fund amount, total The total amount of funds during the period. Marketable Securities Marketable securities Investment in marketable securities Guarantee Of Notes Guarantee of notes The value of guarantee notes during the period. Guarantee Of Checks Guarantee of checks The value of guarantee checks during the period. Fair Value, by Balance Sheet Grouping [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Financial assets Investments, Fair Value Disclosure Investment in marketable securities Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Financial liabilities Derivative Liability, Current Derivative liabilities Derivative liabilities Embedded Derivative, Fair Value of Embedded Derivative, Net Derivative liabilities embedded conversion options Financial Instruments Textual [Abstract] Financial Instruments (Textual) Gain Loss On Fair Value Hedges Unrecognized In Earnings Gross unrecognized gain (loss) Total amount of gain (loss) derived from fair value hedges unrecognized in earnings in the period. Gain (Loss) on Fair Value Hedges Recognized in Earnings Recognized loss Fair Value, Option, Changes in Fair Value, Gain (Loss) Fair value Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Equity Award [Domain] Equity Awards [Member] Equity Awards [Member] Equity awards. Liability Awards [Member] Liabilities awards. Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Allocated Share-based Compensation Expense Stock-based compensation expense Allocated Share Based Compensation Expense Expenses were recognized fair value Stock-based compensation expense Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table] Consultant [Member] Consultant 1 [Member] Consultant Two [Member] Consultant 2 [Member] Financial Consultant [Member] Consultant 3 [Member] Five Installment [Member] Sixth Installment [Member] Range [Axis] Range [Domain] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items] Stock Based Compensation Textual [Abstract] Stock Based Compensation (Textual) Proceeds From Sale Of Common Stock Shares Consideration for the sale of shares The cash inflow from the sale of common stock that has been previously reacquired by the entity. Common Stock Of Share Transferred In Installment Common stock of share transferred in installment It represent Common stock of share transferred in installment for the reporting period. Stock Issued During Period, Shares, Issued for Services Common stock issued for financing and strategic advisory, for such consulting services Consideration for services of common stock Shares Issued, Price Per Share Exercise price Fair Value Disclosure Cost Fair value disclosure, cost It represent fair value cost or sum for the reporting period Debt Instrument, Fair Value Disclosure Debt instrument, fair value disclosure Option To Purchase Common Stock Options to purchase common stock Options to purchase common stock. Investment Options, Exercise Price Common stock exercise price Share-based Compensation Arrangement by Share-based Payment Award, Description Share-based compensation exercisable, description Other Expenses Expenses, amount EX-101.PRE 10 mysz-20170930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 12, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	My Size, Inc.
Entity Central Index Key	0001211805
Trading Symbol	MYSZ
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		18,394,817

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Interim Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 14	$ 34
Other receivables and prepaid expenses	304	1,401
Restricted cash	69	62
Total current assets	387	1,497
Investment in marketable securities	246	579
Property and equipment, net	67	74
Total noncurrent assets	313	653
Total assets	700	2,150
Current liabilities
Trade payable	315	229
Accounts payable	442	316
Warrants, Derivative and share based liabilities	435	80
Total current liabilities	1,192	625
COMMITMENTS AND CONTINGENCIES
Stockholders' equity (Deficit):
Common stock of $ 0.001 par value - Authorized: 50,000,000 shares; Issued and outstanding: 18,078,218 and 17,405,359 As of September 30, 2017 and December 31, 2016, respectively	18	17
Additional paid-in capital	14,740	13,347
Available for sale reserve		(93)
Accumulated other comprehensive loss	(87)	(102)
Accumulated deficit	(15,163)	(11,644)
Total stockholders' equity (Deficit)	(492)	1,525
Total liabilities and stockholders' equity	$ 700	$ 2,150

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Interim Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	18,078,218	17,405,359
Common stock, shares outstanding	18,078,218	17,405,359

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Interim Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Operating expenses
Research and development	$ 213	$ 172	$ 624	$ 500	$ 727
Marketing, General and administrative	611	434	2,667	1,359	1,859
Total operating expenses	824	606	3,291	1,859	2,586
Operating loss	(824)	(606)	(3,291)	(1,859)	(2,586)
Financial (expenses) income, net	17	(118)	(228)	(2,261)	(1,748)
Net loss from continuing operations	(807)	(724)	(3,519)	(4,120)	(4,334)
Other comprehensive loss:
Gain (loss) on available for sale securities	67	(527)	93	67	(24)
Foreign currency translation differences	16	35	15	(49)	2
Total comprehensive loss	$ (724)	$ (1,216)	$ (3,411)	$ (4,102)	$ (4,356)
Basic and diluted loss per share	$ (0.04)	$ (0.04)	$ (0.19)	$ (0.26)	$ (0.27)
Basic and diluted weighted average number of shares outstanding	17,625,440	16,584,354	17,599,340	15,741,967	16,345,499

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands

Total

Common stock

Additional paid-in capital

Available for sale reserve

Accumulated Deficit

Foreign currency transaction

Balance at Dec. 31, 2015

$ (2,613)

$ 15

$ 4,853

$ (67)

$ (7,310)

$ (104)

Balance, shares at Dec. 31, 2015

15,313,793

Total comprehensive loss

(4,102)

(4,120)

(49)

Stock-based compensation related to options granted to consultants

(33)

Warrants converted and exercised into equity

1,041

Convertible loans converted to equity

6,730

$ 2

6,728

Convertible loans converted to equity, shares

2,091,566

Balance at Sep. 30, 2016

1,023

$ 17

12,589

(11,430)

(153)

Balance, shares at Sep. 30, 2016

17,405,359

Balance at Dec. 31, 2015

(2,613)

$ 15

4,853

(67)

(7,310)

(104)

Balance, shares at Dec. 31, 2015

15,313,793

Total comprehensive loss

(4,356)

(24)

(4,334)

Stock-based compensation related to options granted to consultants

(23)

Warrants converted and exercised into equity

987

Convertible loans converted to equity

7,530

$ 2

7,528

Convertible loans converted to equity, shares

2,091,566

Balance at Dec. 31, 2016

1,525

$ 17

13,347

(93)

(11,644)

(102)

Balance, shares at Dec. 31, 2016

17,405,359

Balance at Jun. 30, 2016

804

$ 15

11,155

527

(10,706)

(187)

Balance, shares at Jun. 30, 2016

15,313,793

Total comprehensive loss

(1,216)

(527)

(724)

Stock-based compensation related to options granted to consultants

(39)

Convertible loans converted to equity

1,475

$ 2

1,473

Convertible loans converted to equity, shares

2,091,566

Balance at Sep. 30, 2016

1,023

$ 17

12,589

(11,430)

(153)

Balance, shares at Sep. 30, 2016

17,405,359

Balance at Dec. 31, 2016

1,525

$ 17

13,347

(93)

(11,644)

(102)

Balance, shares at Dec. 31, 2016

17,405,359

Total comprehensive loss

(3,411)

(3,519)

Stock-based compensation related to options granted to consultants

126

Warrants converted and exercised into equity

^[1]

Warrants converted and exercised into equity, shares

80,359

Issuance and receipts on account of shares

1,208

$ 1

$ 1,207

Issuance and receipts on account of shares, shares

592,500

1,208

Balance at Sep. 30, 2017

(492)

$ 18

$ 14,740

(15,163)

(87)

Balance, shares at Sep. 30, 2017

18,078,218

Balance at Jun. 30, 2017

(457)

$ 17

14,052

(67)

(14,356)

(103)

Balance, shares at Jun. 30, 2017

17,605,359

Total comprehensive loss

(724)

(807)

Stock-based compensation related to options granted to consultants

Warrants converted and exercised into equity

^[1]

Warrants converted and exercised into equity, shares

80,359

Issuance and receipts on account of shares

576

$ 1

575

Issuance and receipts on account of shares, shares

392,500

Balance at Sep. 30, 2017

$ (492)

$ 18

$ 14,740

$ (15,163)

$ (87)

Balance, shares at Sep. 30, 2017

18,078,218

[1]	Less than $1.

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Interim Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (807)	$ (724)	$ (3,519)	$ (4,120)	$ (4,334)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	7	6	22	17	24
Amortization of warrant, convertible loans and derivative	(101)	117	(251)	2,260	(182)
Revaluation of PUT options					776
Revaluation of investment in marketable securities	132		472		1,233
Stock based compensation- equity	53	(39)	126	(33)	(23)
Stock based compensation- liability	88		265
Decrease (increase) in receivables and prepaid expenses	61	(39)	115	(43)	(27)
Increase in derivative liabilities	(27)		126		80
Increase (decrease) in trade payable	127	(62)	64	44	86
Increase (decrease) in other accounts payable	(60)	57	108	127	208
Net cash used in operating activities	(527)	(684)	(2,472)	(1,748)	(2,159)
Cash flows from investing activities:
Purchase of property and equipment	(1)	(8)	(8)	(31)	(36)
Net cash used in investing activities	(1)	(8)	(8)	(31)	(36)
Cash flows from financing activities:
Repayment of a loan			(10)	(25)	(25)
Proceeds from issuance of shares, warrants and convertible loans	491	739	2,506	1,043	1,339
Net cash provided by financing activities	491	739	2,496	1,018	1,314
Effect of exchange rate changes on cash and cash equivalents	(77)	(2)	(36)	(15)	(4)
Increase (Decrease) in cash and cash equivalents	(114)	45	(20)	(776)	(885)
Cash and cash equivalents at the beginning of the period	128	98	34	919	919
Cash and cash equivalents at the end of the period	14	143	14	143	34
Non cash transactions
Warrants reclassified to equity as a result of amended exercise price currency				987	987
Conversion of loan to equity				$ 4,939	$ 4,846

XML 17 R7.htm IDEA: XBRL DOCUMENT

General

9 Months Ended

Sep. 30, 2017

General [Abstract]

General

Note 1 - General

Since February 2014, the Company also operates via a wholly-owned subsidiary, My Size (Israel) 2014 Ltd., a company registered in Israel.

The financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Significant Accounting Policies [Abstract]

Significant Accounting Policies

Note 2 - Significant Accounting Policies

Unaudited condensed consolidated interim financial statements:

Use of estimates:

XML 19 R9.htm IDEA: XBRL DOCUMENT

Financial Instruments

9 Months Ended

Sep. 30, 2017

Financial Instruments [Abstract]

Financial Instruments

Note 3 - Financial Instruments

Fair value of financial instruments:

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

	Level 1 -	Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.
	Level 2 -	Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
	Level 3 -	Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends.

September 30, 2017

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities

246

	September 30, 2017
	Fair value hierarchy
	Level 1		Level 2		Level 3
Financial liabilities
Derivative liabilities		-		299		-
Warrants and share based liabilities		-		136		-

December 31, 2016

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities

579

December 31, 2016

Fair value hierarchy

Level 1

Level 2

Level 3

Financial liabilities

Derivative liabilities

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Stock Based Compensation

9 Months Ended

Sep. 30, 2017

Stock Based Compensation [Abstract]

Stock Based Compensation

Note 4 - Stock Based Compensation

	Nine months ended September 30,					Three months ended September 30,					Year ended December 31,
	2017		2016			2017		2016			2016

Stock-based compensation expense - equity awards		126		(33	)		53		(39	)		(23	)
Stock-based compensation expense - liability awards		265		-			88		-			-

		391		(33	)		141		(39	)		(23	)

Following initial grant, the Company reclassified the options from equity accounted under ASC 505-50 to derivative liability accounted under ASC 815.

An amount of $88 and $27 was recorded in the balance sheet as warrants and share based liabilities and share based payments respectively.

During the nine-month period ended September 30, 2017, costs in the sum of $76 were recorded by the Company as stock-based compensation expense- equity awards.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Contingencies and Commitments

9 Months Ended

Sep. 30, 2017

Contingencies and Commitments [Abstract]

Contingencies and Commitments

Note 5 - Contingencies and Commitments

Further to Note 10a to the Annual Report on Form 10-K for the year ended December 31, 2016:

XML 22 R12.htm IDEA: XBRL DOCUMENT

Significant Events During the Reporting Period

9 Months Ended

Sep. 30, 2017

Significant Events During the Reporting Period [Abstract]

Significant Events During the Reporting Period

Note 6 - Significant Events During the Reporting Period

	a.	In February 2017, the Board of Directors approved agreements with investors that will provide an investment for a total amount of $200 in exchange for 200,000 shares of common stock of the Company. In addition, the Company will issue warrants exercisable for an aggregate of 250,000 shares of common stock of the Company until December 22, 2017 at an exercise price of $3.50 per share.

	b.	On June 5, 2017, the Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC notifying the Company that for the preceding 30 consecutive business days, the Company’s common stock did not maintain a minimum Market Value of Listed Securities of $35 million (“MVLS Requirement”) per share as required by NASDAQ Listing Rule 5550(b)(2).

On August 16 2017, the Board of Directors approved agreements with three private investors who will provide investment totaling $780 in exchange for 780,000 shares of common stock of the Company.

	d.	On September 26, 2017, the Company was notified (the “Notification Letter”) by The NASDAQ Stock Market, LLC (“NASDAQ”) that it is not in compliance with the minimum bid price requirements set forth in NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and NASDAQ Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on The NASDAQ Capital Market and, at this time, the common stock will continue to trade on The NASDAQ Capital Market under the symbol “MYSZ”.

		The Notification Letter provides that the Company has 180 calendar days, or until March 26, 2018, to regain compliance with NASDAQ Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by March 26, 2018, an additional 180 days may be granted to regain compliance, so long as the Company meets The NASDAQ Capital Market continued listing requirements (except for the bid price requirement) and notifies NASDAQ in writing of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then NASDAQ will notify the Company of its determination to delist the Company's common stock, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel.

		The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the minimum bid price requirement under the NASDAQ Listing Rules.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

Note 7 - Subsequent Events

XML 24 R14.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2017

Significant Accounting Policies [Abstract]

Unaudited condensed consolidated financial statements:

Unaudited condensed consolidated interim financial statements:

Use of estimates:

XML 25 R15.htm IDEA: XBRL DOCUMENT

Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2017

Financial Instruments [Abstract]

Schedule of significant assets and liabilities that are measured at fair value on recurring basis

September 30, 2017

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities

246

	September 30, 2017
	Fair value hierarchy
	Level 1		Level 2		Level 3
Derivative liabilities		-		299		-
Warrants and share based liabilities		-		136		-

December 31, 2016

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities

579

December 31, 2016

Fair value hierarchy

Level 1

Level 2

Level 3

Financial liabilities

Derivative liabilities

XML 26 R16.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Stock Based Compensation [Abstract]

Summary of stock based expense (income) recognized for services received from non-employees

	Nine months ended September 30,					Three months ended September 30,					Year ended December 31,
	2017		2016			2017		2016			2016

Stock-based compensation expense - equity awards		126		(33	)		53		(39	)		(23	)
Stock-based compensation expense - liability awards		265		-			88		-			-

		391		(33	)		141		(39	)		(23	)

XML 27 R17.htm IDEA: XBRL DOCUMENT

General (Details) $ in Thousands	Sep. 30, 2017 USD ($)
General (Textual)
Accumulated loss	$ 15,100
Guarantee notes [Member]
General (Textual)
Guarantee of notes	1,177
Guarantee of checks	455
Fund raising agreements [Member]
General (Textual)
Cash	5,753
Aggregate raised, amount	8,795
Marketable securities	$ 1,410

XML 28 R18.htm IDEA: XBRL DOCUMENT

Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Financial liabilities
Derivative liabilities	$ 299	$ 80
Warrants, Derivative and share based liabilities	435	80
Level 1 [Member]
Financial assets
Investment in marketable securities	246	579
Financial liabilities
Derivative liabilities
Warrants, Derivative and share based liabilities
Level 2 [Member]
Financial assets
Investment in marketable securities
Financial liabilities
Derivative liabilities	299	80
Warrants, Derivative and share based liabilities	136
Level 3 [Member]
Financial assets
Investment in marketable securities
Financial liabilities
Derivative liabilities
Warrants, Derivative and share based liabilities

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References + Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Financial Instruments (Details Textual) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Financial Instruments (Textual)
Gross unrecognized gain (loss)		$ 24
Recognized loss	$ 472	1,233
Fair value	$ 246	$ 579

XML 30 R20.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
Stock Based Compensation (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 141	$ (39)	$ 391	$ (33)	$ (23)
Equity Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	53	(39)	126	(33)	(23)
Liability Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 88		$ 265

XML 31 R21.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Details Textual) $ / shares in Units, ¥ in Thousands, $ in Thousands	1 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2018 ₪ / shares shares	Apr. 30, 2017	Sep. 30, 2017 USD ($)	Dec. 31, 2016 $ / shares shares	Dec. 31, 2016 CNY (¥) shares	Sep. 26, 2017 $ / shares	May 16, 2017 $ / shares	Sep. 30, 2016 USD ($)
Stock Based Compensation (Textual)
Fair value disclosure, cost \| $			$ (4)					$ 90
Debt instrument, fair value disclosure \| $			124					$ 80
Expenses, amount \| $			186
Strike price \| $ / shares						$ 1
Agreement period					18 months
Warrants and share based liabilities \| $			88
Share based payments \| $			27
Subsequent Event [Member]
Stock Based Compensation (Textual)
Common stock of share transferred in installment \| shares	500,000
Exercise price \| ₪ / shares	₪ 18
Consultant 1 [Member]
Stock Based Compensation (Textual)
Consideration for the sale of shares \| ¥					¥ 500
Consideration for services of common stock \| shares					25,000
Share price falls on the stock exchange, percentage					90.00%
Common stock, exercisable \| shares				40,000	40,000
Consultant 2 [Member]
Stock Based Compensation (Textual)
Options to purchase common stock \| shares					2,000,000
Share-based compensation exercisable, description					The Company agreed to issue to Consultant2 options to purchase up to 2,000,000 shares of the Company’s common stock at variable exercise prices ranging from $3.50 to $9.00 per share. The options are exercisable for periods ranging from 12 months (or 6 months from filing date of registration statement) to 36 months.
Consultant 2 [Member] \| Maximum [Member]
Stock Based Compensation (Textual)
Common stock exercise price \| $ / shares				$ 9.00
Strike price \| $ / shares							$ 5.00
Consultant 2 [Member] \| Minimum [Member]
Stock Based Compensation (Textual)
Common stock exercise price \| $ / shares				$ 3.50
Strike price \| $ / shares							$ 1.50
Consultant 3 [Member]
Stock Based Compensation (Textual)
Common stock issued every quarter, description		The Company agreed to pay a monthly retainer and to issue to the Consultant3 50,000 shares of the Company common stock and 31,250 shares each quarter thereafter.
Sum of cost \| $			$ 76
Five Installment [Member]
Stock Based Compensation (Textual)
Consideration for services of common stock \| shares					4,150
Sixth Installment [Member]
Stock Based Compensation (Textual)
Consideration for services of common stock \| shares					4,250

XML 32 R22.htm IDEA: XBRL DOCUMENT

Contingencies and Commitments (Details) $ in Thousands	1 Months Ended	9 Months Ended
Contingencies and Commitments (Details) $ in Thousands	Apr. 27, 2017 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2017 ILS (₪)	Sep. 30, 2017 ILS (₪)
Contingencies and Commitments (Textual)
Plaintiff damaged value	$ 18,800
Name of plaintiff, description		The Company agreed to issue, within 60 days, 80,358 additional shares of common stock to the plaintiff (the “New Shares”), which New Shares shall be registered, to be deposited in escrow and sold for the benefit of plaintiff. To the extent the Company will not issue the unrestricted New Shares within 60 days of the Settlement, the plaintiff has a right, at his sole discretion, to resume the legal proceedings pursuant to the Complaint, provided he deposits the Down Payment in an escrow account, pending the Court’s final adjudication of the Complaint. Additionally, the Settlement provides that to the extent the aggregate proceeds from the sale of the Original Shares and the New Shares is less than NIS1,600,000, the Company will either complement the difference in cash or shall issue to the plaintiff additional shares of common stock in lieu thereof, at the Company’s sole discretion.	The Company agreed to issue, within 60 days, 80,358 additional shares of common stock to the plaintiff (the “New Shares”), which New Shares shall be registered, to be deposited in escrow and sold for the benefit of plaintiff. To the extent the Company will not issue the unrestricted New Shares within 60 days of the Settlement, the plaintiff has a right, at his sole discretion, to resume the legal proceedings pursuant to the Complaint, provided he deposits the Down Payment in an escrow account, pending the Court’s final adjudication of the Complaint. Additionally, the Settlement provides that to the extent the aggregate proceeds from the sale of the Original Shares and the New Shares is less than NIS1,600,000, the Company will either complement the difference in cash or shall issue to the plaintiff additional shares of common stock in lieu thereof, at the Company’s sole discretion.
Issued bank guarantee lessor \| ₪				₪ 1,700,000,000
Share based liabilities		$ 91
Plaintiffs costs \| ₪			₪ 70,000
Liability was converted into equity		60
Record of derivative		176
Issued shares equity recorded		$ 60
Defendants [Member]
Contingencies and Commitments (Textual)
Name of plaintiff, description		The Company and plaintiff entered into a settlement agreement (the “Settlement”) dated June 20, 2017 following a mediation process. Pursuant to the Settlement, the Company agreed to make a payment to the plaintiff of NIS325,000 (the “Down Payment”) within 30 days of the date of the Settlement. Additionally, the Company is obligated to register the Original Shares within a specified time frame. Moreover, pursuant to the Settlement.	The Company and plaintiff entered into a settlement agreement (the “Settlement”) dated June 20, 2017 following a mediation process. Pursuant to the Settlement, the Company agreed to make a payment to the plaintiff of NIS325,000 (the “Down Payment”) within 30 days of the date of the Settlement. Additionally, the Company is obligated to register the Original Shares within a specified time frame. Moreover, pursuant to the Settlement.

XML 33 R23.htm IDEA: XBRL DOCUMENT

Significant Events During the Reporting Period (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended
	Jun. 05, 2017	Sep. 26, 2017	Feb. 28, 2017	Sep. 30, 2017	Aug. 16, 2017
Significant Events During the Reporting Period (Textual)
Investments			$ 200
Exchange of common stock, shares			200,000
Non-negotiable warrants exercisable			250,000
Exercise price of warrants			$ 3.50
Investment warrants exercisable, expiration date			Dec. 22, 2017
Written notice received, description		The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and NASDAQ Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company no longer meets the minimum bid price requirement.
Closing bid price		$ 1
Listing Qualifications Department [Member]
Significant Events During the Reporting Period (Textual)
Written notice received, description	The Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC notifying the Company that for the preceding 30 consecutive business days, the Company’s common stock did not maintain a minimum Market Value of Listed Securities of $35 million (“MVLS Requirement”) per share as required by NASDAQ Listing Rule 5550(b)(2).
Board of Directors [Member]
Significant Events During the Reporting Period (Textual)
Investments in cash					$ 341
Remaining amount of investment received				$ 236
Exchange shares of common stock					780,000
Investment total amount					$ 780

XML 34 R24.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Textual) - Subsequent Event [Member]	1 Months Ended
	Oct. 26, 2017 $ / shares
Subsequent Events (Textual)
Exercise price of warrants	$ 0.75
Description of warrants	My Size, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) to sell original issue discount non-convertible notes (the “Notes”) and warrants (the “Warrants”) to certain accredited investors in a private placement transaction (the “Offering”). In connection with the Offering, the Company issued (i) Notes with a principal amount of $1.33 million and (ii) 888,888 Warrants. The Offering resulted in gross proceeds to the Company of approximately $1.2 million, before deducting placement agent and other offering expenses.
Term of warrants	5 years

EXCEL 35 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 36 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 37 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 110 136 1 true 23 0 false 7 false false R1.htm 001 - Document - Document and Entity Information Sheet http://mysizeid.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Condensed Consolidated Interim Balance Sheets Sheet http://mysizeid.com/role/CondensedConsolidatedInterimBalanceSheets Condensed Consolidated Interim Balance Sheets Statements 2 false false R3.htm 003 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical) Sheet http://mysizeid.com/role/CondensedConsolidatedInterimBalanceSheetsParenthetical Condensed Consolidated Interim Balance Sheets (Parenthetical) Statements 3 false false R4.htm 004 - Statement - Condensed Consolidated Interim Statements of Comprehensive Loss Sheet http://mysizeid.com/role/CondensedConsolidatedInterimStatementsOfComprehensiveLoss Condensed Consolidated Interim Statements of Comprehensive Loss Statements 4 false false R5.htm 005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) Sheet http://mysizeid.com/role/CondensedConsolidatedInterimStatementsOfChangesInStockholdersEquityDeficitUnaudited Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 006 - Statement - Condensed Consolidated Interim Statements of Cash Flows Sheet http://mysizeid.com/role/CondensedConsolidatedInterimStatementsOfCashFlows Condensed Consolidated Interim Statements of Cash Flows Statements 6 false false R7.htm 007 - Disclosure - General Sheet http://mysizeid.com/role/General General Notes 7 false false R8.htm 008 - Disclosure - Significant Accounting Policies Sheet http://mysizeid.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 009 - Disclosure - Financial Instruments Sheet http://mysizeid.com/role/FinancialInstruments Financial Instruments Notes 9 false false R10.htm 010 - Disclosure - Stock Based Compensation Sheet http://mysizeid.com/role/StockBasedCompensation Stock Based Compensation Notes 10 false false R11.htm 011 - Disclosure - Contingencies and Commitments Sheet http://mysizeid.com/role/ContingenciesAndCommitments Contingencies and Commitments Notes 11 false false R12.htm 012 - Disclosure - Significant Events During the Reporting Period Sheet http://mysizeid.com/role/Significanteventsduringreportingperiodthe Significant Events During the Reporting Period Notes 12 false false R13.htm 013 - Disclosure - Subsequent Events Sheet http://mysizeid.com/role/SubsequentEvents Subsequent Events Notes 13 false false R14.htm 014 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mysizeid.com/role/Significantaccountingpoliciespolicies Significant Accounting Policies (Policies) Policies http://mysizeid.com/role/SignificantAccountingPolicies 14 false false R15.htm 015 - Disclosure - Financial Instruments (Tables) Sheet http://mysizeid.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://mysizeid.com/role/FinancialInstruments 15 false false R16.htm 016 - Disclosure - Stock Based Compensation (Tables) Sheet http://mysizeid.com/role/StockBasedCompensationTables Stock Based Compensation (Tables) Tables http://mysizeid.com/role/StockBasedCompensation 16 false false R17.htm 017 - Disclosure - General (Details) Sheet http://mysizeid.com/role/GeneralDetails General (Details) Details http://mysizeid.com/role/General 17 false false R18.htm 018 - Disclosure - Financial Instruments (Details) Sheet http://mysizeid.com/role/FinancialInstrumentsDetails Financial Instruments (Details) Details http://mysizeid.com/role/FinancialInstrumentsTables 18 false false R19.htm 019 - Disclosure - Financial Instruments (Details Textual) Sheet http://mysizeid.com/role/FinancialInstrumentsDetailsTextual Financial Instruments (Details Textual) Details http://mysizeid.com/role/FinancialInstrumentsTables 19 false false R20.htm 020 - Disclosure - Stock Based Compensation (Details) Sheet http://mysizeid.com/role/StockBasedCompensationDetails Stock Based Compensation (Details) Details http://mysizeid.com/role/StockBasedCompensationTables 20 false false R21.htm 021 - Disclosure - Stock Based Compensation (Details Textual) Sheet http://mysizeid.com/role/StockBasedCompensationDetailsTextual Stock Based Compensation (Details Textual) Details http://mysizeid.com/role/StockBasedCompensationTables 21 false false R22.htm 022 - Disclosure - Contingencies and Commitments (Details) Sheet http://mysizeid.com/role/ContingenciesAndCommitmentsDetails Contingencies and Commitments (Details) Details http://mysizeid.com/role/ContingenciesAndCommitments 22 false false R23.htm 023 - Disclosure - Significant Events During the Reporting Period (Details) Sheet http://mysizeid.com/role/Significanteventsduringreportingperioddetailsthe Significant Events During the Reporting Period (Details) Details http://mysizeid.com/role/Significanteventsduringreportingperiodthe 23 false false R24.htm 024 - Disclosure - Subsequent Events (Details Textual) Sheet http://mysizeid.com/role/SubsequentEventsDetailsTextual Subsequent Events (Details Textual) Details http://mysizeid.com/role/SubsequentEvents 24 false false All Reports Book All Reports mysz-20170930.xml mysz-20170930.xsd mysz-20170930_cal.xml mysz-20170930_def.xml mysz-20170930_lab.xml mysz-20170930_pre.xml http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 41 0001213900-17-011753-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-17-011753-xbrl.zip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�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end